[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1828
1. Vargun R, Aktug T, Heper A, Bingol-kologlu M: Effects of intrauterine treatment on interstitial cells of Cajal in gastroschisis. J Pediatr Surg; 2007 May;42(5):783-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of intrauterine treatment on interstitial cells of Cajal in gastroschisis.
  • AIM: An experimental study was performed to investigate the effects of amnio-allantoic fluid exchange and intrauterine bicarbonate treatment on intestinal damage and interstitial cells of Cajal (ICC) in gastroschisis.
  • MATERIALS AND METHODS: Thirteen-day-old fertilized chick eggs were randomly allocated into 4 groups as control, gastroschisis, gastroschisis + amnio-allantoic fluid exchange, and gastroschisis + bicarbonate treatment groups.
  • In the treatment groups, amnio-allantoic exchange and bicarbonate treatments were performed for 3 days, after creating gastroschisis.
  • Specimens were processed for hematoxylin-eosin and c-kit immunohistochemistry on the 18th day of incubation, after macroscopic examination.
  • The intestines were evaluated with light microscopy for the presence of mucosal congestion and muscular and serosal edema.
  • Mean muscular thickness and density of ICC were measured.
  • RESULTS: Mean muscular thickness significantly increased in the gastroschisis group when compared with control and treatment groups.
  • Labeling intensity, morphology, and localization of the ICC were similar in all groups.
  • Mean ICC density significantly decreased in the gastroschisis group when compared with the control group (P < .01), and it significantly increased after amnio-allantoic fluid exchange treatment (P < .01).
  • CONCLUSIONS: The decrease in ICC density encountered in damaged intestinal loops in gastroschisis was prevented with intrauterine treatment.
  • The beneficial effects of amniotic exchange on intestinal motility may depend on both prevention of intestinal damage and preservation of ICC density and function.
  • The density of ICC might be a reliable numeric parameter both to predict intestinal motility disorders in gastroschisis and to compare the effectiveness of intrauterine treatment methods.
  • [MeSH-major] Allantois. Amniotic Fluid. Bicarbonates / pharmacology. Gastroschisis / embryology. Gastroschisis / therapy. Intestines / cytology. Muscle, Smooth / cytology
  • [MeSH-minor] Animals. Chick Embryo. Drainage / methods. Gastrointestinal Motility. Random Allocation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17502183.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bicarbonates
  •  go-up   go-down


2. Krappmann P, Paulides M, Stöhr W, Ittner E, Plattig B, Nickel P, Lackner H, Schrappe M, Janka G, Beck JD, Langer T: Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up. Pediatr Hematol Oncol; 2007 Mar;24(2):101-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up.
  • In a multicenter study the authors prospectively investigated neurocognitive function in childhood ALL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cognition Disorders / chemically induced. Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454775.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin; ALL-BFM-95 protocol
  •  go-up   go-down


3. Shigeta T, Imadome K, Sakamoto S, Fukuda A, Kakiuchi T, Matsuno N, Tanaka H, Nakazawa A, Kasahara M: Epstein-Barr virus infection after pediatric living-related liver transplantation--management and risk factors. Transplant Proc; 2010 Dec;42(10):4178-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus infection after pediatric living-related liver transplantation--management and risk factors.
  • INTRODUCTION: Posttransplant lymphoproliferative disorder (PTLD) is one of the severe complications after pediatric liver transplantation.
  • The incidence of acute rejection episodes and cytomegalovirus infections; ABO blood type incompatible LRLT, and the length of steroid treatment and the additional immunosuppression were not significantly different between the two groups.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21168657.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System
  •  go-up   go-down


Advertisement
4. El-Hout Y, Salle JL, Al-Saad T, Bägli DJ, Lorenzo AJ, Neilson B, Farhat WA: Do patients with classic bladder exstrophy have fecal incontinence? A web-based study. Urology; 2010 May;75(5):1166-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were analyzed as 2 groups: pediatric (age up to 18 years, n = 69, 9 excluded for not achieving toilet training) and adult (age >18 years, n = 25).
  • In the pediatric group, fecal incontinence was reported in 57% of patients during the day and 32% during night.
  • Stratifying patients based on US diversion showed fecal incontinence of 100% vs 22% during the day (P <.001), and 86% vs 22% during the night (P <.01), for the US vs non-US subgroups, respectively.

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • Genetic Alliance. consumer health - Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Urology. 2010 May;75(5):1168-9; author reply 1169 [20451738.001]
  • (PMID = 19914696.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Gold JI, Montano Z, Shields S, Mahrer NE, Vibhakar V, Ybarra T, Yee N, Upperman J, Blake N, Stevenson K, Nager AL: Pediatric disaster preparedness in the medical setting: integrating mental health. Am J Disaster Med; 2009 May-Jun;4(3):137-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric disaster preparedness in the medical setting: integrating mental health.
  • OBJECTIVE: To provide an overview and recommendations for the integration of mental health considerations into pediatric disaster preparedness and response in the medical setting.
  • METHODS: Recommendations were developed by a panel of disaster preparedness and mental health experts during the Childrens Hospital Los Angeles Pediatric Disaster Resource and Training Center: Workshop on Family Reunification in Los Angeles, California, March 31-April 1, 2008.
  • CONCLUSIONS: The inclusion of mental health concerns into pediatric disaster preparedness may help prevent further and unnecessary psychological harm to children and adolescent survivors following a disaster.


6. Claret Teruel G, Giner Muñoz MT, Plaza Martín AM, Martín Mateos MA, Piquer Gibert M, Sierra Martínez JI: Variability of immunodeficiency associated with ataxia telangiectasia and clinical evolution in 12 affected patients. Pediatr Allergy Immunol; 2005 Nov;16(7):615-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven patients were treated with non-specific gamma-globulin.

  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Ataxia Telangiectasia.
  • MedlinePlus Health Information. consumer health - Ataxia Telangiectasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16238588.001).
  • [ISSN] 0905-6157
  • [Journal-full-title] Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
  • [ISO-abbreviation] Pediatr Allergy Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Gantz BJ, Dunn CC, Walker EA, Kenworthy M, Van Voorst T, Tomblin B, Turner C: Bilateral cochlear implants in infants: a new approach--Nucleus Hybrid S12 project. Otol Neurotol; 2010 Oct;31(8):1300-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: Eight pediatric patients with profound bilateral sensorineural hearing loss between the ages of 12 and 24 months.

  • MedlinePlus Health Information. consumer health - Cochlear Implants.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acoust Soc Am. 2005 May;117(5):3091-9 [15957777.001]
  • [Cites] Nature. 2006 Jun 22;441(7096):984-7 [16791196.001]
  • [Cites] J Assoc Res Otolaryngol. 2007 Jun;8(2):241-57 [17347777.001]
  • [Cites] Ear Hear. 2007 Aug;28(4):470-82 [17609610.001]
  • [Cites] Otol Neurotol. 2008 Feb;29(2):160-7 [18025998.001]
  • [Cites] Ear Hear. 2008 Jun;29(3):352-9 [18453885.001]
  • [Cites] Laryngoscope. 2005 May;115(5):796-802 [15867642.001]
  • [Cites] Audiol Neurootol. 2010;15(1):44-56 [19468210.001]
  • [Cites] Otol Neurotol. 2010 Oct;31(8):1227-32 [20802370.001]
  • [Cites] Otol Neurotol. 2002 Mar;23(2):169-80 [11875346.001]
  • [Cites] Am J Otol. 1995 Mar;16(2):186-99 [8572119.001]
  • [Cites] Nat Med. 2005 Mar;11(3):271-6 [15711559.001]
  • [Cites] Audiol Neurootol. 2009;14 Suppl 1:32-8 [19390173.001]
  • (PMID = 20802369.001).
  • [ISSN] 1537-4505
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / P50 DC000242; United States / NIDCD NIH HHS / DC / 5 P50 DC00242; United States / NCRR NIH HHS / RR / M01-RR-59
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS232998; NLM/ PMC2951013
  •  go-up   go-down


8. Bhutani VK, Maisels MJ, Stark AR, Buonocore G, Expert Committee for Severe Neonatal Hyperbilirubinemia, European Society for Pediatric Research, American Academy of Pediatrics: Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants &gt;or=35 weeks gestation. Neonatology; 2008;94(1):63-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants >or=35 weeks gestation.
  • Kernicterus is still occurring but should be largely preventable if health care personnel follow the recommendations listed in this guideline.
  • These recommendations emphasize the importance of universal, systematic assessment of the risk of severe hyperbilirubinemia, lactation support, close follow-up, and prompt intervention when necessary.
  • A systems-based approach to prevent severe neonatal hyperbilirubinemia should be implemented at all birthing facilities and coordinated with continuing ambulatory care.
  • Translational research is needed to better understand the mechanisms of bilirubin neurotoxicity and potential therapeutic interventions.
  • [MeSH-major] Hyperbilirubinemia, Neonatal / prevention & control. Jaundice, Neonatal / therapy. Kernicterus / prevention & control
  • [MeSH-minor] Humans. Infant, Newborn. Practice Guidelines as Topic

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18204221.001).
  • [ISSN] 1661-7819
  • [Journal-full-title] Neonatology
  • [ISO-abbreviation] Neonatology
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Number-of-references] 39
  • [Investigator] Buonocore G; Ebbessen F; Hansen TW; Dani C; Devictor D; Hallman M; Hoyer P; Manning D; Mercier JC; Rubaltelli FF; Saugstad OD; Speer CP; Stiris T; Fabris C; Carbonell-Estrany X; Kaplan M; Maisels MJ; Stevenson DK; Bhutani VK; Stark AR; Lannon C; Tiribelli C; Ostrow JD; Ahlfors CE; Brites D; Ghersi-Egea JF; Vitek L; Lorusso V; Tell G; Verkade H; Watchko JF; Wennberg RP; Zucker S
  •  go-up   go-down


9. Brassesco MS, Cortez MA, Valera ET, Engel EE, Nogueira-Barbosa MH, Becker AP, Scrideli CA, Tone LG: Cryptic SYT/SXX1 fusion gene in high-grade biphasic synovial sarcoma with unique complex rearrangement and extensive BCL2 overexpression. Cancer Genet Cytogenet; 2010 Jan 15;196(2):189-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cryptic SYT/SXX1 fusion gene in high-grade biphasic synovial sarcoma with unique complex rearrangement and extensive BCL2 overexpression.
  • Synovial sarcomas are high-grade malignant mesenchymal tumors that account for 10% of all soft-tissue sarcomas.
  • Almost 95% of these tumors are characterized by a nonrandom chromosomal abnormality, t(X;18)(p11.2;q11.2), that is observed in both biphasic and monophasic variants.
  • In this article, we present the case of a 57-year-old woman diagnosed with high-grade biphasic synovial sarcoma in which conventional cytogenetic analysis revealed the constant presence of a unique t(18;22)(q12;q13), in addition to trisomy 8.
  • The rearrangement was confirmed by fluorescence in situ hybridization.
  • The use of the whole chromosome painting probes WCPX did not detect any rearrangements involving chromosome X, although reverse-transcriptase polymerase chain reaction (PCR) analysis demonstrated the conspicuous presence of a SYT/SXX1 fusion gene.
  • Spectral karyotyping (SKY) was also performed and revealed an insertion of material from chromosome 18 into one of the X chromosomes at position Xp11.2.
  • Thus, the karyotype was subsequently interpreted as 47,X,der(X)ins(X;18)(p11.2;q11.2q11.2),der(18)del(18)(q11.2q11.2)t(18;22)(q12;q13),der(22)t(18;22).
  • Real-time PCR analysis of BCL2 expression in the tumor sample showed a 433-fold increase.
  • This rare finding exemplifies that thorough molecular-cytogenetic analyses are required to elucidate complex and/or cryptic tumor-specific translocations.
  • [MeSH-major] Gene Rearrangement. Genes, bcl-2. Proto-Oncogene Proteins / genetics. Repressor Proteins / genetics. Sarcoma, Synovial / genetics
  • [MeSH-minor] Base Sequence. DNA Primers. Female. Gene Fusion. Humans. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20082858.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / SS18 protein, human
  •  go-up   go-down


10. Stanulla M, Schäffeler E, Arens S, Rathmann A, Schrauder A, Welte K, Eichelbaum M, Zanger UM, Schrappe M, Schwab M: GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hematol; 2005 Jan;81(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia.
  • The probability of event-free survival of childhood acute lymphoblastic leukemia (ALL) approaches 80% or more with the use of modern multiagent chemotherapeutic regimens.
  • In a matched case-control study, we investigated the associations between CNS relapse in childhood ALL and the presence of phenotypically relevant single nucleotide polymorphisms within the GSTP1 (codon 105 and 114) and MDR1 genes (ABCB1; coding for Pgp; exon 26, C3435T).
  • These results suggested a modulating role for host genetic variation in the development of CNS relapse in childhood ALL treated according to Berlin-Frankfurt-Münster protocols.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Glutathione Transferase / genetics. Isoenzymes / genetics. P-Glycoprotein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] J Clin Invest. 1996 Jun 1;97(11):2517-24 [8647944.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] Pharmacol Ther. 1990;48(3):357-69 [2084706.001]
  • [Cites] Pharmacogenetics. 1998 Feb;8(1):27-31 [9511178.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 18;238(2):397-402 [9299520.001]
  • [Cites] Blood. 1994 Jul 15;84(2):355-66 [8025264.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:161-83 [8725386.001]
  • [Cites] Gastroenterology. 2000 Feb;118(2):279-88 [10648456.001]
  • [Cites] J Am Soc Nephrol. 2002 Jul;13(7):1847-54 [12089380.001]
  • [Cites] N Engl J Med. 2003 Apr 10;348(15):1442-8 [12686700.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8 [10716719.001]
  • [Cites] Carcinogenesis. 1997 Apr;18(4):641-4 [9111193.001]
  • [Cites] Neuropathol Appl Neurobiol. 1990 Aug;16(4):293-303 [2234311.001]
  • [Cites] Eur J Haematol. 2004 May;72(5):314-21 [15059065.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Jan 21;55(1):83-105 [12535575.001]
  • [Cites] Joint Bone Spine. 2000 Jan;67(1):30-9 [10773966.001]
  • [Cites] Ann Hum Genet. 1989 Jul;53(Pt 3):205-13 [2596826.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Pharmacogenetics. 2001 Jun;11(4):293-8 [11434506.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] Pharmacogenetics. 2000 Nov;10(8):715-26 [11186134.001]
  • [Cites] Eur J Biochem. 1994 Sep 15;224(3):893-9 [7925413.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:285-307 [12359865.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 15717687.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / P-Glycoprotein; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


11. Vrabelova Z, Kolouskova S, Böhmova K, Faresjö MK, Sumnik Z, Pechova M, Kverka M, Chudoba D, Zacharovova K, Stadlerova G, Pithova P, Hladikova M, Stechova K: Protein microarray analysis as a tool for monitoring cellular autoreactivity in type 1 diabetes patients and their relatives. Pediatr Diabetes; 2007 Oct;8(5):252-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein microarray analysis as a tool for monitoring cellular autoreactivity in type 1 diabetes patients and their relatives.
  • BACKGROUND: Autoreactive T cells have a crucial role in type 1 diabetes (T1D) pathogenesis.
  • OBJECTIVES: The aim of our study was to monitor the in vitro production of cytokines by peripheral blood mononuclear cells (PBMCs) after stimulation with diabetogenic autoantigens.
  • SUBJECTS: Ten T1D patients (tested at the time of diagnosis and 6 and 12 months later), 10 first-degree relatives of the T1D patients, and 10 controls underwent the study.
  • METHODS: PBMCs were stimulated with glutamic acid decarboxylase 65 (GAD65) amino acids (a.a.
  • ) 247-279, 509-528, and 524-543; proinsulin a.a.
  • 9-23; and tyrosine phosphatase (islet antigen-2)/R2 a.a. 853-872.
  • Interleukin (IL)-2, IL-4, IL-5, IL-6, IL-10, IL-13, interferon (IFN)-gamma, tumor necrosis factor beta, transforming growth factor beta1, and granulocyte colony-stimulating factor (GCSF) were analyzed by protein microarray.
  • RESULTS: Differences in cytokine(s) poststimulatory and mainly in basal production were observed in all groups.
  • The most prominent findings were in controls, the higher basal levels of IL-2, IL-4, IL-5, IL-13, and GCSF were observed when compared with relatives (p < 0.05, for all).
  • After stimulation in controls, there was a significant decrease in IL-2, IL-13, GCSF, and IFN-gamma (p < 0.05, for all).
  • The group of relatives was the most variable in poststimulatory production.
  • A strong correlation between cytokines production was found but groups differed in this aspect.
  • CONCLUSION: By multiplex analysis, it may be possible, for example, to define the risk immunological response pattern among relatives or to monitor the immune response in patients on immune modulation therapy.
  • [MeSH-major] Cytokines / genetics. Diabetes Mellitus, Type 1 / genetics. Diabetes Mellitus, Type 1 / immunology. Protein Array Analysis
  • [MeSH-minor] Adolescent. Amino Acid Sequence. Autoantibodies / genetics. Child. Child, Preschool. Family. Female. Glutamate Decarboxylase / chemistry. Glutamate Decarboxylase / genetics. Humans. Interleukins / genetics. Male. Molecular Sequence Data

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850467.001).
  • [ISSN] 1399-543X
  • [Journal-full-title] Pediatric diabetes
  • [ISO-abbreviation] Pediatr Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Cytokines; 0 / Interleukins; EC 4.1.1.15 / Glutamate Decarboxylase; EC 4.1.1.15 / glutamate decarboxylase 2
  •  go-up   go-down


12. Stams WA, Beverloo HB, den Boer ML, de Menezes RX, Stigter RL, van Drunen E, Ramakers-van-Woerden NL, Loonen AH, van Wering ER, Janka-Schaub GE, Pieters R: Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome. Leukemia; 2006 Mar;20(3):410-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome.
  • Clinical heterogeneity within t(12;21) or TEL/AML1-positive ALL (25% of childhood common/preB ALL) indicates that additional genetic changes might contribute to outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 21. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424874.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


13. Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Høiby N: Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol; 2009 Jun;44(6):547-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-mucoid bacteria were not observed here, and rarely in the conductive zone (1/9).
  • Non-mucoid and planktonic P. aeruginosa were also observed here (3/3).In conclusion, the present intensive antibiotic therapy of chronic P. aeruginosa infections, at the Copenhagen CF Centre, seems to restrain but not eradicate the bacteria from the conductive zone, whereas the remaining healthy respiratory zone appears to be protected, for a long period, from massive biofilm infection.


14. Gurofsky RC, Sabharwal T, Manlhiot C, Redington AN, Benson LN, Chahal N, McCrindle BW: Arterial complications associated with cardiac catheterization in pediatric patients with a previous history of Kawasaki disease. Catheter Cardiovasc Interv; 2009 May 1;73(6):809-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arterial complications associated with cardiac catheterization in pediatric patients with a previous history of Kawasaki disease.
  • All patients who experienced complications had multiple large and/or giant coronary artery aneurysms and two were within 3 months of the acute phase of KD.
  • Odds for arterial complications in patients with KD were 10.4 times greater (95%CI: 3.2-33.8) than that noted for the general pediatric cardiac catheterization population (3.6% vs. 0.4%, P < 0.0001) which indicates higher risk associated with arterial access in patients with KD.
  • CONCLUSIONS: Greater care in obtaining arterial access for angiography is warranted, especially in the first month directly following the acute phase, possibly related to systemic arterial damage associated with KD.

  • Genetic Alliance. consumer health - Kawasaki Disease.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Congenital Heart Defects.
  • MedlinePlus Health Information. consumer health - Kawasaki Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180654.001).
  • [ISSN] 1522-726X
  • [Journal-full-title] Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • [ISO-abbreviation] Catheter Cardiovasc Interv
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.5 / Thrombin
  •  go-up   go-down


15. Goldstein SL, Graham N, Burwinkle T, Warady B, Farrah R, Varni JW: Health-related quality of life in pediatric patients with ESRD. Pediatr Nephrol; 2006 Jun;21(6):846-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life in pediatric patients with ESRD.
  • As part of creating a pediatric ESRD-specific Health-Related Quality of Life (HRQOL) assessment instrument, we established pilot data with the PedsQL 4.0 Generic Core Scales in 96 pediatric patients with ESRD receiving hemodialysis (HD), peritoneal dialysis (PD) or with a renal transplant (TX).
  • Our data demonstrate that the PedsQL 4.0 Generic Core Scales is a useful measurement instrument to screen for HRQOL impairment in pediatric patients with ESRD.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Behav Med. 2002 Apr;25(2):175-93 [11977437.001]
  • [Cites] Pediatr Nephrol. 1991 Sep;5(5):612-6 [1911149.001]
  • [Cites] Pediatr Nephrol. 1995 Oct;9(5):553-7 [8580008.001]
  • [Cites] Ambul Pediatr. 2003 Nov-Dec;3(6):329-41 [14616041.001]
  • [Cites] Kidney Int. 2001 Mar;59(3):1121-7 [11231369.001]
  • [Cites] Pediatr Nephrol. 2002 Jul;17(7):531-4 [12172769.001]
  • [Cites] Am J Kidney Dis. 1999 Oct;34(4 Suppl 2):S40-6 [10516375.001]
  • [Cites] Med Care. 2001 Aug;39(8):800-12 [11468499.001]
  • [Cites] Am J Kidney Dis. 2004 Nov;44(5 Suppl 2):39-46 [15486873.001]
  • [Cites] Am J Kidney Dis. 2004 Dec;44(6):1017-23 [15558522.001]
  • [Cites] Pediatrics. 1984 Aug;74(2):273-8 [6379590.001]
  • [Cites] Pediatr Nephrol. 1994 Dec;8(6):744-9 [7696117.001]
  • [Cites] Am J Kidney Dis. 2002 Feb;39(2):257-65 [11840365.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2090-106 [11932914.001]
  • [Cites] Am J Kidney Dis. 2000 Feb;35(2):293-300 [10676729.001]
  • [Cites] Pediatr Nephrol. 1999 Nov;13(9):766-70 [10603116.001]
  • [Cites] Nephrol Dial Transplant. 2000;15 Suppl 3:23-8 [11032354.001]
  • [Cites] Pediatr Nephrol. 2004 Nov;19(11):1262-6 [15368119.001]
  • [Cites] Gen Hosp Psychiatry. 1995 Jan;17(1):32-6 [7737493.001]
  • [Cites] Urology. 2000 Aug 1;56(2):201-6 [10925078.001]
  • (PMID = 16703376.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


16. Haining WN, Wherry EJ: Integrating genomic signatures for immunologic discovery. Immunity; 2010 Feb 26;32(2):152-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrating genomic signatures for immunologic discovery.
  • Understanding heterogeneity in adaptive immune responses is essential to dissect pathways of memory B and T cell differentiation and to define correlates of protective immunity.
  • Traditionally, immunologists have deconvoluted this heterogeneity with flow cytometry--with combinations of markers to define signatures that represent specific lineages, differentiation states, and functions.
  • Genome-scale technologies have become widely available and provide the ability to define expression signatures--sets of genes--that represent discrete biological properties of cell populations.
  • Because genomic signatures can serve as surrogates of a phenotype, function, or cell state, they can integrate phenotypic information between experiments, cell types, and species.
  • Here, we discuss how integration of well-defined expression signatures across experimental conditions together with functional analysis of their component genes could provide new opportunities to dissect the complexity of the adaptive immune response and map the immune response to vaccines and pathogens.
  • [MeSH-major] B-Lymphocytes / immunology. Gene Expression Profiling. T-Lymphocytes / immunology
  • [MeSH-minor] Adaptive Immunity / genetics. Adaptive Immunity / immunology. Animals. Computational Biology. Drug Discovery. Humans. Immunologic Memory. Immunophenotyping. Lymphocyte Activation / genetics. Species Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20189480.001).
  • [ISSN] 1097-4180
  • [Journal-full-title] Immunity
  • [ISO-abbreviation] Immunity
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI071309; United States / NIAID NIH HHS / AI / AI082630; United States / PHS HHS / / HHSN266200500030C
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Jialin G, Xuefan G, Huiwen Z: SID1 transmembrane family, member 2 (Sidt2): a novel lysosomal membrane protein. Biochem Biophys Res Commun; 2010 Nov 26;402(4):588-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SID1 transmembrane family, member 2 (Sidt2): a novel lysosomal membrane protein.
  • In a recent proteomic study of lysosomal proteins [10], we identified SID1 transmembrane family, member 2 (Sidt2) as a novel lysosomal membrane protein candidate.
  • The Sidt2 gene encodes an 832-amino acid residues protein with a calculated molecular mass of 94.5kDa.
  • Bioinformatic analysis showed that Sidt2 is a multipass transmembrane protein that contains 10 putative N-glycosylation sites (NxS/T) and two potential tyrosine-based sorting signals (YGSF and YDTL).
  • Using specific anti-Sidt2 antibody and lysosomal markers, the lysosomal localization of Sidt2 was determined by immunofluorescence.
  • Furthermore, using subcellular fractionation techniques, we demonstrated that Sidt2 is a lysosomal integral membrane protein.
  • Endogenous Sidt2 was detected in multiple tissues of mouse and rat with approximately 120-130kDa molecular weights due to extensive glycosylation.
  • After digestion with PNGase F, the apparent molecular mass of Sidt2 decreased to the predicted value of 95kDa.
  • In rats, Sidt2 was highly expressed in the liver, brain, and kidney, whereas no or little expression was found in the skeletal muscles, heart, and other tissues.
  • In summary, Sidt2 is a highly glycosylated lysosomal integral membrane protein that shows tissue-specific expression.
  • [MeSH-major] Lysosomes / metabolism. Membrane Glycoproteins / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line. Glycosylation. Liver / metabolism. Liver / ultrastructure. Mice. Molecular Sequence Data. NIH 3T3 Cells. Rats. Tissue Distribution

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20965152.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Sidt2 protein, mouse; 0 / Sidt2 protein, rat
  •  go-up   go-down


18. Catchpole KR, de Leval MR, McEwan A, Pigott N, Elliott MJ, McQuillan A, MacDonald C, Goldman AJ: Patient handover from surgery to intensive care: using Formula 1 pit-stop and aviation models to improve safety and quality. Paediatr Anaesth; 2007 May;17(5):470-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cardiac Surgical Procedures. Continuity of Patient Care / standards. Intensive Care Units, Pediatric / organization & administration. Models, Organizational. Patient Care Management / standards. Patient Transfer / standards. Total Quality Management / organization & administration

  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474955.001).
  • [ISSN] 1155-5645
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


19. Malhotra A, Gaur S, Whitley-Williams P, Loomis C, Petrova A: Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study. AIDS Res Ther; 2007;4:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study.
  • RESULTS: A cross sectional study was conducted to evaluate the impact of treatment regimens and resistance mutation patterns on the clinical, virological, and immunological presentation of HIV disease in 41 children (25 male and 16 female) at the Robert Wood Johnson Pediatric AIDS Program in New Brunswick, New Jersey.
  • The study participants were symptomatic and had preceding treatment history with combined ARV regimens including protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).
  • CONCLUSION: Primary PR resistance mutations significantly increase the likelihood for high viral replication in pediatric patients with moderate/severe HIV-1 infection, which may affect the long-term clinical prognosis of the HIV infected children.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1998 Oct 22;12(15):2007-15 [9814869.001]
  • [Cites] J Clin Invest. 1998 Nov 15;102(10):1769-75 [9819361.001]
  • [Cites] J Virol. 2002 Dec;76(23):12344-8 [12414975.001]
  • [Cites] JAMA. 2000 Jan 19;283(3):381-90 [10647802.001]
  • [Cites] N Engl J Med. 2001 Feb 15;344(7):472-80 [11172188.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):385-94 [12167680.001]
  • [Cites] HIV Clin Trials. 2002 May-Jun;3(3):237-48 [12032883.001]
  • [Cites] Antivir Ther. 2001;6 Suppl 3:45-54 [11678472.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 Sep 20;17(14):1321-8 [11602042.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Mar 1;26 Suppl 1:S25-33 [11264999.001]
  • [Cites] Ann Intern Med. 1998 Jun 1;128(11):906-11 [9634429.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] N Engl J Med. 1997 Sep 11;337(11):734-9 [9287228.001]
  • [Cites] JAMA. 1997 Jun 25;277(24):1962-9 [9200638.001]
  • [Cites] Ann Intern Med. 1997 Jun 15;126(12):939-45 [9182470.001]
  • [Cites] Ann Intern Med. 1997 Jun 15;126(12):929-38 [9182469.001]
  • [Cites] J Infect Dis. 1996 Nov;174(5):962-8 [8896496.001]
  • [Cites] J Virol. 1996 Feb;70(2):1086-90 [8551567.001]
  • [Cites] Nature. 1995 Apr 6;374(6522):569-71 [7700387.001]
  • [Cites] Science. 1995 Jan 27;267(5197):483-9 [7824947.001]
  • [Cites] Science. 1993 Mar 19;259(5102):1749-54 [8096089.001]
  • [Cites] J Virol. 1995 Aug;69(8):5087-94 [7541846.001]
  • [Cites] Nature. 1995 Jan 12;373(6510):117-22 [7529365.001]
  • [Cites] Expert Opin Biol Ther. 2002 Oct;2(7):751-61 [12387674.001]
  • [Cites] J Virol. 2002 Sep;76(18):9253-9 [12186909.001]
  • [Cites] J Clin Microbiol. 2002 Dec;40(12):4512-9 [12454144.001]
  • [Cites] Virology. 2003 Mar 1;307(1):116-21 [12667819.001]
  • [Cites] Infez Med. 2002 Sep;10(3):151-6 [12704265.001]
  • [Cites] Clin Infect Dis. 2003 Jul 1;37(1):113-28 [12830416.001]
  • [Cites] J Antimicrob Chemother. 2003 Oct;52(4):547-50 [12951341.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2003 Sep;98(6):831-7 [14595464.001]
  • [Cites] Pediatr Infect Dis J. 2004 Jan;23(1):15-22 [14743040.001]
  • [Cites] Scand J Infect Dis Suppl. 2003;106:61-6 [15000587.001]
  • [Cites] J Antimicrob Chemother. 2004 May;53(5):696-9 [15044425.001]
  • [Cites] Clin Exp Immunol. 2004 Sep;137(3):570-7 [15320908.001]
  • [Cites] Clin Microbiol Infect. 2004 Sep;10(9):826-30 [15355414.001]
  • [Cites] Top HIV Med. 2004 Oct-Nov;12(4):119-24 [15516709.001]
  • [Cites] Top HIV Med. 2005 Mar-Apr;13(1):51-7 [15849371.001]
  • [Cites] HIV Med. 2005 Nov;6(6):403-9 [16268822.001]
  • [Cites] J Clin Virol. 2005 Dec;34(4):288-94 [16286052.001]
  • [Cites] BMC Infect Dis. 2006;6:10 [16433913.001]
  • [Cites] Science. 1990 Sep 28;249(4976):1533-44 [1699273.001]
  • (PMID = 17620130.001).
  • [ISSN] 1742-6405
  • [Journal-full-title] AIDS research and therapy
  • [ISO-abbreviation] AIDS Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1959238
  •  go-up   go-down


20. Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH Jr, Fontana RJ, Lee WM, Schilsky ML, Pediatric and Adult Acute Liver Failure Study Groups: Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology; 2008 Oct;48(4):1167-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests.
  • Acute liver failure (ALF) due to Wilson disease (WD) is invariably fatal without emergency liver transplantation.
  • Serum copper levels exceeded 200 microg/dL in all ALF-WD patients measured (13/16), but were also elevated in non-WD ALF.

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Wilson disease.
  • MedlinePlus Health Information. consumer health - Health Screening.
  • MedlinePlus Health Information. consumer health - Wilson Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2008 Oct;48(4):1030-2 [18821595.001]
  • [CommentIn] Hepatology. 2009 May;49(5):1783-4; author reply 1784 [19402113.001]
  • [CommentIn] Hepatology. 2009 Jul;50(1):329 [19333910.001]
  • (PMID = 18798336.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK058369; United States / NIDDK NIH HHS / DK / U01 DK058369; United States / NIDDK NIH HHS / DK / R-01-DK 56389
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 789U1901C5 / Copper; EC 1.16.3.1 / Ceruloplasmin; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.3.1 / Alkaline Phosphatase; RFM9X3LJ49 / Bilirubin
  • [Other-IDs] NLM/ NIHMS456838; NLM/ PMC4881751
  • [Investigator] Lee WM; Polson J; Pezzia C; Lalani E; Hynan LS; Reisch JS; Larson AM; Do H; Crippin JS; Gerstle L; Davern TJ; Partovi K; Emre S; McCashland TM; Bernard T; Hay J; Groettum C; Murray N; Coultrup S; Shakil AO; Morton D; Blei AT; Gottstein J; Zaman A; Schwartz J; Ingram K; Han S; Peacock V; Fontana RJ; Welch S; McGuire B; Avant L; Chung R; Casson D; Brown R Jr; Schilsky M; Senkbeil L; Harrison ME; Rush R; Reuben A; Huntley N; Munoz S; Misra C; Stravitz T; Salvatori J; Rossaro L; Prosser C; Satyanarayana R; Taylor W; Reddy R; Campbell M; Hassenein T; Barakat F; Smith A
  •  go-up   go-down


21. Poretti A, Boltshauser E, Loenneker T, Valente EM, Brancati F, Il'yasov K, Huisman TA: Diffusion tensor imaging in Joubert syndrome. AJNR Am J Neuroradiol; 2007 Nov-Dec;28(10):1929-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion tensor imaging in Joubert syndrome.
  • BACKGROUND AND PURPOSE: Neuropathologic findings and preliminary imaging studies demonstrated the absence of pyramidal tract and superior cerebellar peduncular decussation in individual patients with Joubert syndrome (JS).
  • We hypothesized that functional-structural neuroimaging findings do not differ between the genetic forms of JS.
  • MATERIALS AND METHODS: MR imaging was performed with a 3T MR imaging-unit.
  • Multiplanar T2- and T1-weighted imaging was followed by diffusion tensor imaging (DTI).
  • Isotropic diffusion-weighted images, apparent diffusion coefficient maps, and color-coded fractional anisotropy maps, including tractography, were subsequently calculated.
  • RESULTS: In all 6 patients studied, DTI showed that the fibers of the superior cerebellar peduncles did not decussate in the mesencephalon and the corticospinal tract failed to cross in the caudal medulla.
  • The patients represented various genetic forms of JS.
  • CONCLUSION: In JS, the fibers of the pyramidal tract and the superior cerebellar peduncles do not cross, irrespective of the underlying mutation.
  • [MeSH-major] Abnormalities, Multiple / pathology. Brain / abnormalities. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Cerebellum / pathology. Child. Humans. Pyramidal Tracts / pathology. Syndrome

  • Genetic Alliance. consumer health - Joubert Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17898198.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Chang HH, Lu MY, Jou ST, Lin KH, Tien HF, Lin DT: Cytogenetics in childhood acute lymphoblastic leukemia in Taiwan: a single-institutional experience. Pediatr Hematol Oncol; 2006 Sep;23(6):495-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics in childhood acute lymphoblastic leukemia in Taiwan: a single-institutional experience.
  • [MeSH-major] Chromosome Aberrations / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


23. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB: Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol; 2009 Jun;4(6):1051-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study reports the first measurements of bioactive serum hepcidin using a novel competitive ELISA in 48 pediatric (PCKD2-4) and 32 adult (ACKD2-4) patients with stages 2 to 4 CKD along with 26 pediatric patients with stage 5 CKD (PCKD5D) on peritoneal dialysis.
  • RESULTS: When compared with their respective controls (pediatric median = 25.3 ng/ml, adult = 72.9 ng/ml), hepcidin was significantly increased in PCKD2-4 (127.3 ng/ml), ACKD2-4 (269.9 ng/ml), and PCKD5D (652.4 ng/ml).

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Chronic Kidney Disease.
  • MedlinePlus Health Information. consumer health - Iron.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Nov 15;112(10):4292-7 [18689548.001]
  • [Cites] Nephrol Dial Transplant. 2008 Sep;23(9):2879-83 [18326562.001]
  • [Cites] Kidney Int. 2009 May;75(9):976-81 [19212416.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7806-10 [11113131.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7811-9 [11113132.001]
  • [Cites] Nephrol Dial Transplant. 2001;16 Suppl 7:36-40 [11590255.001]
  • [Cites] Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 [11904577.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):1037-44 [12370282.001]
  • [Cites] Nephrol Dial Transplant. 2002;17 Suppl 11:39-43 [12386257.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2461-3 [12433676.001]
  • [Cites] Am J Kidney Dis. 2003 Oct;42(4):761-73 [14520627.001]
  • [Cites] J Clin Invest. 2004 May;113(9):1271-6 [15124018.001]
  • [Cites] Clin Chem Lab Med. 2004 Apr;42(4):387-9 [15147148.001]
  • [Cites] Pediatr Clin North Am. 1987 Jun;34(3):571-90 [3588043.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]
  • [Cites] Gut. 2005 Jan;54(1):169-70 [15591524.001]
  • [Cites] J Endocrinol. 2005 Feb;184(2):361-70 [15684344.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1011-23 [15758012.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1864-6 [15886319.001]
  • [Cites] Am J Kidney Dis. 2006 May;47(5 Suppl 3):S11-145 [16678659.001]
  • [Cites] Am J Clin Nutr. 2006 Jul;84(1):150-5 [16825689.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1381-7 [16621968.001]
  • [Cites] Am J Hematol. 2006 Nov;81(11):832-7 [16929540.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3730-5 [16882706.001]
  • [Cites] J Am Soc Nephrol. 2007 Feb;18(2):394-400 [17229910.001]
  • [Cites] Kidney Blood Press Res. 2007;30(1):15-30 [17215586.001]
  • [Cites] Br J Nutr. 2007 Mar;97(3):544-9 [17313717.001]
  • [Cites] Kidney Int. 2007 Jun;71(11):1163-71 [17396118.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Sep;1 Suppl 1:S4-8 [17699374.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Sep;1 Suppl 1:S9-18 [17699375.001]
  • [Cites] Am J Nephrol. 2008;28(1):115-21 [17943020.001]
  • [Cites] Blood Cells Mol Dis. 2008 May-Jun;40(3):339-46 [18023212.001]
  • [Cites] PLoS One. 2008;3(7):e2706 [18628991.001]
  • [Cites] Nephrol Dial Transplant. 2008 Aug;23(8):2450-3 [18495744.001]
  • [CommentIn] Clin J Am Soc Nephrol. 2009 Jun;4(6):1015-6 [19470661.001]
  • (PMID = 19406957.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 5R01DK067563-04; United States / NIDDK NIH HHS / DK / R01 DK067563; United States / NIDDK NIH HHS / DK / R01 DK065029; United States / NIDDK NIH HHS / DK / 1K08DK074284-01; United States / NIDDK NIH HHS / DK / K08 DK074284
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Biomarkers; 0 / HAMP protein, human; 0 / Hepcidins; 0 / Iron-Binding Proteins; 0 / Receptors, Cell Surface; 0 / ferritin receptor; 9007-41-4 / C-Reactive Protein; 9007-73-2 / Ferritins; E1UOL152H7 / Iron
  • [Other-IDs] NLM/ PMC2689881
  •  go-up   go-down


24. van Tijn DA, de Vijlder JJ, Verbeeten B Jr, Verkerk PH, Vulsma T: Neonatal detection of congenital hypothyroidism of central origin. J Clin Endocrinol Metab; 2005 Jun;90(6):3350-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal detection of congenital hypothyroidism of central origin.
  • Due to the high frequency of concurrent pituitary hormone deficiencies, congenital hypothyroidism (CH) of central origin (CH-C) is a life-threatening disorder.
  • Yet only a minority of these patients are detected by neonatal CH screening programs worldwide.
  • We conducted a prospective multicenter study involving a 2-yr cohort of neonatally diagnosed CH-C patients to determine whether a T(4)-TSH-based neonatal CH screening protocol extended with T(4) binding globulin determinations improves early detection of CH-C and to assess the extent of pituitary hormone deficiency among the identified CH-C patients.
  • In all infants with screening results indicative of CH-C, the functional integrity of the hypothalamo-hypophyseal system was investigated by dynamic tests; the anatomical integrity was investigated by magnetic resonance imaging.
  • Initial test results were evaluated after 5 yr of follow-up.
  • Among 385,000 infants screened over the 2-yr period, 19 cases of permanent CH-C were detected (prevalence, 1:20,263; 95% confidence interval, 1:12,976 to 1:33,654), representing 13.5% of all detected cases of permanent CH.
  • The majority (78%) had multiple pituitary hormone deficiency, whereas 53% had pituitary malformations on magnetic resonance imaging.
  • We conclude that infants with CH-C can very well be detected by neonatal screening.
  • The estimated prevalence and the severity of pituitary dysfunction of this treatable disorder call for explicit attention for this entity of CH in neonatal screening programs worldwide.
  • [MeSH-major] Congenital Hypothyroidism. Hypothyroidism / diagnosis
  • [MeSH-minor] Adrenocorticotropic Hormone / blood. Cohort Studies. Female. Human Growth Hormone / blood. Humans. Infant, Newborn. Male. Mass Screening. Netherlands. Pituitary Hormones / blood. Thyroid Function Tests. Thyroid Hormones / blood

  • Genetic Alliance. consumer health - Congenital Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Endocrinol Metab. 2005 Jun;90(6):3797-9 [15917488.001]
  • (PMID = 15784706.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pituitary Hormones; 0 / Thyroid Hormones; 12629-01-5 / Human Growth Hormone; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


25. Lu G, Xie ZD, Zhao SY, Ye LJ, Wu RH, Liu CY, Yang S, Jin YK, Shen KL: Clinical analysis and follow-up study of chronic active Epstein-Barr virus infection in 53 pediatric cases. Chin Med J (Engl); 2009 Feb 5;122(3):262-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis and follow-up study of chronic active Epstein-Barr virus infection in 53 pediatric cases.
  • The characteristics of CAEBV in Mainland Chinese pediatric patients are largely unreported.
  • METHODS: A retrospective study was performed on 53 pediatric patients (36 boys and 17 girls) with CAEBV who were admitted to Beijing Children's Hospital between 2003 and 2007.
  • CONCLUSIONS: The study reveals that CAEBV in Chinese pediatric patients has a severe clinical course and prognosis is poor.

  • Genetic Alliance. consumer health - Epstein Barr Virus, Chronic.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236801.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Serum Albumin
  •  go-up   go-down


26. Betts DR, Cohen N, Leibundgut KE, Kühne T, Caflisch U, Greiner J, Traktenbrot L, Niggli FK: Characterization of karyotypic events and evolution in neuroblastoma. Pediatr Blood Cancer; 2005 Feb;44(2):147-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neuroblastoma (NB) is cytogenetically characterized by a number of non-random events.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15390360.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins
  •  go-up   go-down


27. Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D: Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol; 2010 Aug 10;28(23):3680-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
  • PATIENTS AND METHODS: Five hundred seventy-three pediatric patients with classical HL were enrolled onto the German Society of Pediatric Oncology and Hematology-Hodgkin's Disease (GPOH-HD) -2002 study between November 2002 and December 2005.
  • OPPA-COPP and OEPA-COPDAC seem to be exchangeable regimens in intermediate- and advanced-stage classical HL in pediatric patients.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625128.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; AOPE protocol; OPPA protocol
  •  go-up   go-down


28. Piccaluga PP, Malagola M, Rondoni M, Ottaviani E, Testoni N, Laterza C, Visani G, Pileri SA, Martinelli G, Baccarani M: Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. Leuk Lymphoma; 2006 Mar;47(3):469-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation.
  • The (1;19)(q23;p13) translocation, leading to the production of the E2A/PBX1 fusion transcript, is one of the most common translocations in pediatric B-lineage acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396770.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


29. Sirmaci A, Duman D, Oztürkmen-Akay H, Erbek S, Incesulu A, Oztürk-Hişmi B, Arici ZS, Yüksel-Konuk EB, Taşir-Yilmaz S, Tokgöz-Yilmaz S, Cengiz FB, Aslan I, Yildirim M, Hasanefendioğlu-Bayrak A, Ayçiçek A, Yilmaz I, Fitoz S, Altin F, Ozdağ H, Tekin M: Mutations in TMC1 contribute significantly to nonsyndromic autosomal recessive sensorineural hearing loss: a report of five novel mutations. Int J Pediatr Otorhinolaryngol; 2009 May;73(5):699-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in TMC1 contribute significantly to nonsyndromic autosomal recessive sensorineural hearing loss: a report of five novel mutations.
  • Genome wide homozygosity mapping using Affymetrix 10K arrays revealed the DFNB7/11 locus including the TMC1 gene in 5 of 35 Turkish families with autosomal recessive nonsyndromic severe to profound congenital or prelingual-onset sensorineural hearing loss (SNHL).
  • Additional 51 families were later screened for co-segregation of the locus with the phenotype using microsatellite markers.
  • GJB2 and mtDNA A1555G mutations were negative in probands from each family.
  • Mutation analysis was performed in families showing co-segregation of autosomal recessive SNHL with haplotypes at the DFNB7/11 locus.
  • A total of six different mutations in seven families were identified, including novel missense alterations, p.G444R (c.1330G>A), p.R445C (c.1333C>T), and p.I677T (c.2030T>C), one novel splice site mutation IVS6+2 T>A (c.64+2T>A), and a novel large deletion of approximately 31kb at the 3' region of the gene including exons 19-24, as well as a previously reported nonsense mutation, p.R34X (c.100C>T).
  • All identified mutations co-segregated with autosomal recessive SNHL in all families and were not found in Turkish hearing controls.
  • These results expand the mutation spectrum of TMC1 with five novel mutations and provide data for the significant contribution of TMC1 mutations in hearing loss.
  • [MeSH-major] Hearing Loss, Sensorineural / genetics. Membrane Proteins / genetics. Point Mutation / genetics
  • [MeSH-minor] Bone Conduction. DNA Primers / genetics. DNA, Mitochondrial / genetics. Exons. Haplotypes. Homozygote. Humans. Introns. Pedigree. Phenotype. Polymerase Chain Reaction. Turkey

  • Genetic Alliance. consumer health - Sensorineural hearing loss.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187973.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Mitochondrial; 0 / Membrane Proteins; 0 / TMC1 protein, human
  •  go-up   go-down


30. Ertem M, Ileri T, Azik F, Uysal Z, Gozdasoglu S: Related donor hematopoietic stem cell transplantation for Fanconi anemia without radiation: a single center experience in Turkey. Pediatr Transplant; 2009 Feb;13(1):88-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No patient developed acute GVHD and one patient had chronic GVHD.
  • Based on our data, we conclude that Flu-based, non-irradiation conditioning regimen was safe with low organ toxicity and stable engraftment in FA patients undergoing HSCT from matched related donors.

  • Genetic Alliance. consumer health - Fanconi Anemia.
  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433407.001).
  • [ISSN] 1399-3046
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


31. Chitkara DK, Talley NJ, Weaver AL, Katusic SK, De Schepper H, Rucker MJ, Locke GR 3rd: Incidence of presentation of common functional gastrointestinal disorders in children from birth to 5 years: a cohort study. Clin Gastroenterol Hepatol; 2007 Feb;5(2):186-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Gastroesophageal reflux disease (GERD), abdominal pain of unknown origin, and constipation are thought to be causes for frequent medical visits during childhood.
  • RESULTS: The incidence for childhood (age, <5 y) presentation of GERD, abdominal pain of unknown origin, and constipation was .9/1000 person-years, 4.5/1000 person-years, and 6.8/1000 person-years, respectively; there were no significant differences between boys and girls.
  • CONCLUSIONS: The incidences of presentation for GERD, abdominal pain of unknown origin, and constipation are among the highest for pediatric disorders, and a cause for repeated medical consultations.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901769.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Sabo-Attwood T, Ramos-Nino M, Bond J, Butnor KJ, Heintz N, Gruber AD, Steele C, Taatjes DJ, Vacek P, Mossman BT: Gene expression profiles reveal increased mClca3 (Gob5) expression and mucin production in a murine model of asbestos-induced fibrogenesis. Am J Pathol; 2005 Nov;167(5):1243-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles reveal increased mClca3 (Gob5) expression and mucin production in a murine model of asbestos-induced fibrogenesis.
  • To elucidate genes important in development or repair of asbestos-induced lung diseases, gene expression was examined in mice after inhalation of chrysotile asbestos for 3, 9, and 40 days.
  • We identified changes in the expression of genes linked to proliferation (cyclin B2, CDC20, and CDC28 protein kinase regulatory subunit 2), inflammation (CCL9, CCL6, complement component 1, chitinase3-like 3, TNF superfamily member 10, and IL-1B), and matrix remodeling (MMP12, MMP3, integrin alphaX, and cathepsins K, Z, B, and S).
  • The most highly induced gene at all time points was mclca3 (gob5), a putative calcium-activated chloride channel involved in the regulation of mucus production and/or secretion.
  • Using histochemistry, we demonstrated accumulation of mucus and increased mClca3 protein in the bronchiolar epithelium of asbestos-exposed mice at all time points but peaking at 9 days.
  • Cytokine levels (interleukin-1beta, interleukin-4, interleukin-6) in bronchoalveolar lavage fluid also increased at 9 days, suggesting Th2-mediated immunity may play a role in asbestos-induced mucus production.
  • In contrast, levels of cathepsin K, a potent elastase, increased between 3 and 40 days at both the mRNA and protein levels, localizing primarily in CD45-positive leukocytes and interstitial cells.
  • Identification of genes involved in lung injury and remodeling after asbestos exposure could aid in defining mechanisms of airborne particulate-induced disease and in developing therapeutic strategies.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Pulmonary Fibrosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Cell Mol Biol. 2003 Sep;29(3 Suppl):S51-8 [14503555.001]
  • [Cites] Novartis Found Symp. 2002;248:150-65; discussion 165-70, 277-82 [12568493.001]
  • [Cites] Mol Cell Biochem. 2003 Oct;252(1-2):305-29 [14577606.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Feb;286(2):L320-30 [14527933.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):805-13 [14737115.001]
  • [Cites] Pediatrics. 2004 Apr;113(4 Suppl):1037-43 [15060197.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2203-16 [15161653.001]
  • [Cites] Biochem J. 2004 Jun 15;380(Pt 3):651-9 [15015934.001]
  • [Cites] Eur Respir J. 2004 Jun;23(6):797-8 [15218987.001]
  • [Cites] Mol Pharmacol. 2004 Aug;66(2):337-46 [15266025.001]
  • [Cites] J Clin Invest. 2004 Aug;114(3):438-46 [15286810.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L824-34 [15194565.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Sep 15;170(6):683-90 [15215155.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Oct;31(4):382-94 [15191915.001]
  • [Cites] J Environ Pathol Toxicol. 1980 Jun-Jul;3(5-6):261-75 [7441084.001]
  • [Cites] Chest. 1989 Jul;96(1 Suppl):92S-93S [2544379.001]
  • [Cites] Science. 1990 Jan 19;247(4940):294-301 [2153315.001]
  • [Cites] Environ Health Perspect. 1990 Aug;88:319-22 [2272329.001]
  • [Cites] Am Rev Respir Dis. 1992 Jan;145(1):175-9 [1731581.001]
  • [Cites] Arch Pathol Lab Med. 1992 Jan;116(1):16-20 [1310377.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6305-9 [1330290.001]
  • [Cites] Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):795-802 [8118652.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8458-62 [7667311.001]
  • [Cites] J Toxicol Environ Health. 1995 Oct;46(2):155-69 [7563215.001]
  • [Cites] Eur Respir J. 1999 Sep;14(3):706-16 [10543297.001]
  • [Cites] Toxicol Lett. 2000 Mar 15;112-113:177-83 [10720729.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1307-16 [10751356.001]
  • [Cites] Environ Health Perspect. 1998 Oct;106 Suppl 5:1171-4 [9788893.001]
  • [Cites] J Exp Med. 2000 Sep 18;192(6):789-99 [10993910.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5175-80 [11296262.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1529-36 [11413160.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4368-77 [11591761.001]
  • [Cites] J Pathol. 2001 Oct;195(3):375-82 [11673837.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 9;288(4):747-51 [11688970.001]
  • [Cites] Novartis Found Symp. 2002;248:201-13; discussion 213-20, 277-82 [12568496.001]
  • [Cites] Free Radic Biol Med. 2003 May 1;34(9):1117-29 [12706492.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23243-50 [12690113.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Aug;285(2):L313-21 [12679322.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Sep;285(3):L730-9 [12794003.001]
  • [Cites] Toxicol Lett. 1995 Dec;82-83:483-9 [8597099.001]
  • [Cites] Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1666-80 [9603153.001]
  • [Cites] Am J Physiol. 1998 Jul;275(1 Pt 1):L96-102 [9688940.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Aug;19(2):226-36 [9698594.001]
  • [Cites] J Clin Invest. 1999 Mar;103(6):779-88 [10079098.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Apr;20(4):612-9 [10100992.001]
  • [Cites] J Immunol. 1999 May 15;162(10):6178-83 [10229862.001]
  • [Cites] J Immunol. 1999 May 15;162(10):6233-7 [10229869.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):158-66 [10395285.001]
  • [Cites] J Mol Biol. 2004 Nov 26;344(3):683-95 [15533438.001]
  • [Cites] Zhonghua Jie He He Hu Xi Za Zhi. 2004 Dec;27(12):837-340 [15730785.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):675-84 [15743780.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Apr;32(4):311-8 [15668323.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Oct;25(4):486-91 [11694454.001]
  • [Cites] J Allergy Clin Immunol. 2002 Feb;109(2):246-50 [11842292.001]
  • [Cites] Chest. 2002 Mar;121(3 Suppl):31S-32S [11893671.001]
  • [Cites] J Histochem Cytochem. 2002 Jun;50(6):829-38 [12019299.001]
  • [Cites] Nat Med. 2002 Aug;8(8):885-9 [12091879.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4169-75 [12154012.001]
  • [Cites] J Clin Invest. 2002 Aug;110(4):463-74 [12189240.001]
  • [Cites] J Biol Chem. 2002 Sep 20;277(38):35466-74 [12107190.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Jan;35(1):1-6 [12467641.001]
  • [Cites] Hua Xi Yi Ke Da Xue Xue Bao. 2000 Mar;31(1):58-61 [12501614.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1018-25 [12909582.001]
  • (PMID = 16251409.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL067004; United States / NIEHS NIH HHS / ES / T32 ES007122; United States / NHLBI NIH HHS / HL / HL67004; United States / NIEHS NIH HHS / ES / T32ES07122
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chloride Channels; 0 / Clca3 protein, mouse; 0 / Cytokines; 0 / Mucins; 0 / Mucoproteins; 0 / RNA, Messenger; 1332-21-4 / Asbestos; EC 3.4.21.36 / Pancreatic Elastase
  • [Other-IDs] NLM/ PMC1603789
  •  go-up   go-down


33. Biederman J, Kwon A, Aleardi M, Chouinard VA, Marino T, Cole H, Mick E, Faraone SV: Absence of gender effects on attention deficit hyperactivity disorder: findings in nonreferred subjects. Am J Psychiatry; 2005 Jun;162(6):1083-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: The authors evaluated gender effects in a large group of nonreferred siblings (N=577) of probands with ADHD and non-ADHD comparison subjects.


34. Modi BP, Langer M, Ching YA, Valim C, Waterford SD, Iglesias J, Duro D, Lo C, Jaksic T, Duggan C: Improved survival in a multidisciplinary short bowel syndrome program. J Pediatr Surg; 2008 Jan;43(1):20-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Pediatric short bowel syndrome (SBS) remains a management challenge with significant mortality.
  • In 1999, we initiated a multidisciplinary pediatric intestinal rehabilitation program.

  • Genetic Alliance. consumer health - Short bowel syndrome.
  • Genetic Alliance. consumer health - SHORT syndrome.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr. 2001 Jul;139(1):27-33 [11445790.001]
  • [Cites] J Pediatr Surg. 2007 May;42(5):806-11 [17502188.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1237-41 [16904948.001]
  • [Cites] Pediatrics. 2006 Jul;118(1):e197-201 [16818533.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):804-7 [16567197.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2 Suppl 1):S5-S15 [16473072.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2 Suppl 1):S16-28 [16473066.001]
  • [Cites] J Pediatr. 2004 Aug;145(2):157-63 [15289760.001]
  • [Cites] J Pediatr. 1998 Jan;132(1):80-4 [9470005.001]
  • [Cites] J Pediatr Surg. 1999 Jan;34(1):27-32; discussion 32-3 [10022138.001]
  • [Cites] J Gastrointest Surg. 2005 Feb;9(2):165-76; discussion 176-7 [15694812.001]
  • [Cites] Eur J Pediatr Surg. 2005 Apr;15(2):95-101 [15877257.001]
  • [Cites] J Pediatr Surg. 2005 Jun;40(6):1015-8 [15991188.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):403-9; discussion 409-12 [16135926.001]
  • (PMID = 18206449.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK040561; None / None / / P30 DK040561-12; United States / NIDDK NIH HHS / DK / P30 DK040561-12
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS329316; NLM/ PMC3253359
  •  go-up   go-down


35. Laosombat V, Sattayasevana B, Chotsampancharoen T, Wongchanchailert M: Glucose-6-phosphate dehydrogenase variants associated with favism in Thai children. Int J Hematol; 2006 Feb;83(2):139-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucose-6-phosphate dehydrogenase variants associated with favism in Thai children.
  • In a study conducted at Songklanagarind Hospital in the south of Thailand, the subjects were 225 patients (210 boys and 15 girls) with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  • Favism was found in 3.6% of the G6PD-deficient children.
  • Approximately one half of the G6PD-deficient patients with favism were younger than 2 years.
  • Sudden onset of anemia was found within 1 to 3 days after ingestion of dried fava beans.
  • The classic features of favism, which are pallor, hemoglobinuria, and jaundice, were detected in all cases.
  • To characterize the known G6PD mutations in Thai children, molecular analysis was performed for 8 G6PD-deficient children with favism by a combination of polymerase chain reaction-restriction fragment length polymorphism analysis and amplification refractory mutation system analysis.
  • The G6PD variants in these children were G6PD Kaiping 1388,G-->A; G6PD Mahidol 487,G-->A; G6PD Viangchan 871,G-->A; and uncharacterized mutation with silent mutation 1311,C-->T.
  • [MeSH-major] Favism / genetics. Glucosephosphate Dehydrogenase / genetics. Glucosephosphate Dehydrogenase Deficiency / complications. Polymorphism, Single Nucleotide
  • [MeSH-minor] Child. Child, Preschool. DNA Mutational Analysis / methods. Female. Humans. Infant. Male. Molecular Epidemiology. Retrospective Studies. Thailand / epidemiology

  • MedlinePlus Health Information. consumer health - G6PD Deficiency.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827859475 for PMID:16513531 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2000 Apr;21(4):190-1 [11876979.001]
  • [Cites] Arch Dis Child. 1976 Mar;51(3):233-5 [986125.001]
  • [Cites] Acta Haematol. 1976;56(1):58-64 [822676.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1991 Jun;22(2):176-82 [1948276.001]
  • [Cites] J Med Assoc Thai. 1980 Oct;63(10):537-43 [7441068.001]
  • [Cites] Acta Haematol. 1992;87(1-2):29-31 [1585769.001]
  • [Cites] Am J Hum Genet. 1990 Dec;47(6):1013-9 [1978555.001]
  • [Cites] Hum Genet. 2001 Jun;108(6):445-9 [11499668.001]
  • [Cites] Humangenetik. 1973 Mar 23;18(1):39-46 [4721339.001]
  • [Cites] Int J Hematol. 1999 Dec;70(4):233-5 [10643148.001]
  • [Cites] Am J Hematol. 1994 Dec;47(4):273-7 [7977299.001]
  • [Cites] Blood Cells Mol Dis. 2002 Mar-Apr;28(2):93-103 [12064901.001]
  • [Cites] Hum Genet. 1982;60(3):216-21 [7106752.001]
  • [Cites] J Med Genet. 1969 Sep;6(3):286-91 [5345101.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3613-36 [7949118.001]
  • [Cites] Blood Cells Mol Dis. 2005 Mar-Apr;34(2):191-6 [15727905.001]
  • [Cites] Hum Hered. 1999 Jun;49(3):133-8 [10364676.001]
  • [Cites] J Singapore Paediatr Soc. 1972 Apr;14(1):17-25 [5051872.001]
  • [Cites] Blood Rev. 1996 Mar;10(1):45-52 [8861278.001]
  • [Cites] Hum Mutat. 1999;14(6):477-84 [10571945.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1966;60(2):262-6 [5922616.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):43-7 [12031591.001]
  • [Cites] Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2001 Aug;18(4):259-63 [11484161.001]
  • [Cites] BMJ. 1990 Jan 27;300(6719):236 [2106932.001]
  • [Cites] Hum Mutat. 1999 Oct;14(4):352 [10502785.001]
  • [Cites] Lancet. 1975 Oct 4;2(7936):657 [52023.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:137-41 [8629093.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Oct 31;180(2):988-93 [1953767.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2000 Oct;21(10):509-11 [11877026.001]
  • [Cites] Baillieres Best Pract Res Clin Haematol. 2000 Mar;13(1):21-38 [10916676.001]
  • [Cites] World Health Organ Tech Rep Ser. 1967;366:1-53 [4963040.001]
  • [Cites] Hum Mutat. 2002 Feb;19(2):185 [11793482.001]
  • [Cites] Int J Hematol. 2002 Aug;76(2):149-52 [12215013.001]
  • [Cites] Hum Hered. 1992;42(5):327-9 [1459579.001]
  • [Cites] Bull World Health Organ. 1973;48(1):1-13 [4541143.001]
  • [Cites] Clin Haematol. 1981 Oct;10(3):800-14 [7030553.001]
  • [Cites] Am J Hum Genet. 1990 Dec;47(6):1008-12 [1978554.001]
  • [Cites] Blood. 1992 Aug 15;80(4):1079-82 [1323345.001]
  • [Cites] Acta Haematol. 1991;86(4):179-82 [1805484.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jan-Feb;32(1):112-7 [14757424.001]
  • [Cites] Am J Hematol. 1996 Jan;51(1):19-25 [8571933.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 1999 Apr;20(4):197-9 [11601228.001]
  • [Cites] J Med Genet. 1969 Mar;6(1):34-41 [5771221.001]
  • [Cites] Kaohsiung J Med Sci. 1998 Apr;14(4):197-202 [9589612.001]
  • [Cites] J Med Assoc Thai. 1972 Oct;55(10):576-85 [5081671.001]
  • [Cites] Hum Mol Genet. 1993 Jan;2(1):81-2 [8490627.001]
  • [Cites] Br J Haematol. 1995 Feb;89(2):421-3 [7873396.001]
  • [Cites] Bull World Health Organ. 1989;67(6):601-11 [2633878.001]
  • [Cites] Acta Haematol. 1983;70(2):83-90 [6408883.001]
  • [Cites] Hum Mutat. 2003 Jan;21(1):101 [12497642.001]
  • (PMID = 16513531.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 1.1.1.49 / Glucosephosphate Dehydrogenase
  •  go-up   go-down


36. Hiller A, Meretoja OA, Korpela R, Piiparinen S, Taivainen T: The analgesic efficacy of acetaminophen, ketoprofen, or their combination for pediatric surgical patients having soft tissue or orthopedic procedures. Anesth Analg; 2006 May;102(5):1365-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The analgesic efficacy of acetaminophen, ketoprofen, or their combination for pediatric surgical patients having soft tissue or orthopedic procedures.
  • However, there are no pediatric studies analyzing similar effects when the currently recommended doses of acetaminophen are used.

  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16632811.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics; 362O9ITL9D / Acetaminophen; 76I7G6D29C / Morphine; 90Y4QC304K / Ketoprofen
  •  go-up   go-down


37. Svehlik M, Slaby K, Soumar L, Smetana P, Kobesova A, Trc T: Evolution of walking ability after soft tissue surgery in cerebral palsy patients: what can we expect? J Pediatr Orthop B; 2008 May;17(3):107-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of walking ability after soft tissue surgery in cerebral palsy patients: what can we expect?
  • Eleven patients with spastic cerebral palsy were evaluated preoperatively, and 3 and 9 months postoperatively after soft tissue surgery.
  • Evaluation included clinical examination, the Functional Mobility Scale questionnaire, and instrumented gait and center of mass trajectory analysis.
  • A decrease in time-distance parameters after 3 months was followed by progress in all parameters at 9 months postoperatively.
  • Push-off range of ankle motion decreased after surgery and was not restored to preoperative level until 9 months later.
  • The center of mass vertical displacement improved significantly.
  • The Functional Mobility Scale showed gait improvement.
  • Despite the normalization of range of motion after surgery, there is an obvious period of functional gait deterioration in the early postoperative period and the push-off range of motion at the ankle did not recover to preoperative level until 9 months later.
  • [MeSH-major] Cerebral Palsy / surgery. Equinus Deformity / surgery. Gait. Hip Contracture / surgery. Muscle, Skeletal / surgery. Tendons / surgery
  • [MeSH-minor] Ankle Joint / physiopathology. Child. Female. Hip Joint / physiopathology. Humans. Knee Joint / physiopathology. Male. Muscle Spasticity. Range of Motion, Articular

  • Genetic Alliance. consumer health - Cerebral Palsy.
  • MedlinePlus Health Information. consumer health - Cerebral Palsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391806.001).
  • [ISSN] 1060-152X
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Huang S, Crawford JB, Porco T, Rutar T: Clinicopathologic review of pediatric enucleations during the last 50 years. J AAPOS; 2010 Aug;14(4):328-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic review of pediatric enucleations during the last 50 years.
  • PURPOSE: To evaluate diagnoses leading to enucleations in the pediatric age group over time.
  • The main outcome measures were the frequency of pediatric enucleation specimens in each diagnostic category as compared with total pathological laboratory volume over time, and the age and gender distribution of histopathological diagnostic categories over time.
  • RESULTS: Specimens of 746 eyes from 729 pediatric patients were analyzed.
  • Pediatric enucleated eyes constituted 2.7% of all specimens received at the pathology laboratory.
  • The overall frequency of pediatric enucleation specimens did not change over time.
  • Beginning in the 1980s, pediatric enucleations caused by nonrhegmatogenous retinal detachment, nematode and non-nematode endophthalmitis, and congenital glaucoma decreased significantly.
  • CONCLUSIONS: A decrease in pediatric nonretinoblastoma enucleations was observed over time, possibly attributable to better diagnostic capabilities, surgical techniques, and public health interventions.

  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20736124.001).
  • [ISSN] 1528-3933
  • [Journal-full-title] Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
  • [ISO-abbreviation] J AAPOS
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / P30 EY002162-31
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Yu JW, Borkowski A, Danzig L, Reiter S, Kavan P, Mazer BD: Immune response to conjugated meningococcal C vaccine in pediatric oncology patients. Pediatr Blood Cancer; 2007 Dec;49(7):918-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune response to conjugated meningococcal C vaccine in pediatric oncology patients.
  • We examined the response of pediatric oncology patients during or following maintenance chemotherapy and post-bone-marrow transplantation to Meningococcal C vaccine.
  • The serologic responders had a higher mean B cell count (0.262) compared to non-responders 0.068 x 10.9/L [t(23) = 2.843 (P < 0.05)].
  • Eleven of the 12 non-responders and 4 of the responders were on maintenance chemotherapy.
  • The group included 14/18 serologic responders with hBCA response (P < 0.001) and 16/17 non-serologic responders with no hBCA response (P < 0.001).

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17366523.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Meningococcal Vaccines; 0 / Vaccines, Conjugate
  •  go-up   go-down


40. Suzuki N, Yumura-Yagi K, Yoshida M, Hara J, Nishimura S, Kudoh T, Tawa A, Usami I, Tanizawa A, Hori H, Ito Y, Miyaji R, Oda M, Kato K, Hamamoto K, Osugi Y, Hashii Y, Nakahata T, Horibe K, Japan Association of Childhood Leukemia Study (JACLS): Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol. Pediatr Blood Cancer; 2010 Jan;54(1):71-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol.
  • BACKGROUND: Children with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) after induction therapy (induction failure: IF) have a poor prognosis; however, there have been few prospective studies in patients with IF.
  • Twenty-three of these patients entered the F-protocol study, which mainly consisted of acute-myeloid-leukemia-oriented chemotherapy followed by scheduled hematopoietic cell transplantation (HCT).
  • Of note, 15 (93.8%) of 16 patients with Philadelphia-chromosome-negative (non-Ph(+)) ALL achieved CR; in contrast, only 2 (28.6%) of 7 Ph(+) patients achieved CR.
  • The 5-year overall survival (OS) rates of 16 patients with non-Ph(+) and 7 patients with Ph(+) were 43.8 +/- 12.4% and 14.3 +/- 13.2%, respectively (P = 0.012).
  • CONCLUSION: Acute-myeloid-leukemia-oriented chemotherapy followed by scheduled HCT is a promising treatment strategy for non-Ph(+) ALL patients with IF.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


41. Arbogast KB, Balasubramanian S, Seacrist T, Maltese MR, García-España JF, Hopely T, Constans E, Lopez-Valdes FJ, Kent RW, Tanji H, Higuchi K: Comparison of kinematic responses of the head and spine for children and adults in low-speed frontal sled tests. Stapp Car Crash J; 2009 Nov;53:329-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous research has suggested that the pediatric ATD spine, developed from scaling the adult ATD spine, may not adequately represent a child's spine and thus may lead to important differences in the ATD head trajectory relative to a human.
  • To gain further insight into this issue, the objectives of this study were, through non-injurious frontal sled tests on human volunteers, to 1) quantify the kinematic responses of the restrained child's head and spine and 2) compare pediatric kinematic responses to those of the adult.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20058560.001).
  • [ISSN] 1532-8546
  • [Journal-full-title] Stapp car crash journal
  • [ISO-abbreviation] Stapp Car Crash J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Abdel-Haleem AH, Meki AR, Noaman HA, Mohamed ZT: Serum levels of IL-6 and its soluble receptor, TNF-alpha and chemokine RANTES in scorpion envenomed children: their relation to scorpion envenomation outcome. Toxicon; 2006 Mar 15;47(4):437-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the present study, 30 children in Upper Egypt (less than 12 years old) were admitted to Pediatric Intensive Care Unit because of scorpion envenomation.
  • The non-survival victims (five victims) showed significantly higher mean values of IL-6, sIL-6R, TNF-alpha, RANTES and leucocytic count both on admission and on the follow up samples in comparison to the survivals.
  • Furthermore, those fatal cases showed a non-significant decline in the serum levels of IL-6, sIL-6R, TNF-alpha, RANTES and leucocytic count on the following up samples, while the survivals showed a significant decline in the serum levels of these parameters on the following up samples.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466762.001).
  • [ISSN] 0041-0101
  • [Journal-full-title] Toxicon : official journal of the International Society on Toxinology
  • [ISO-abbreviation] Toxicon
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokine CCL5; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


43. Strengell T, Uhari M, Tarkka R, Uusimaa J, Alen R, Lautala P, Rantala H: Antipyretic agents for preventing recurrences of febrile seizures: randomized controlled trial. Arch Pediatr Adolesc Med; 2009 Sep;163(9):799-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SETTING: Five hospitals, each working as the only pediatric hospital in its region.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Diclofenac / therapeutic use. Seizures, Febrile / prevention & control

  • Genetic Alliance. consumer health - Seizures.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. IBUPROFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Evid Based Med. 2010 Feb;15(1):15-6 [20176873.001]
  • [CommentIn] J Pediatr. 2010 Mar;156(3):507-8 [20176194.001]
  • (PMID = 19736332.001).
  • [ISSN] 1538-3628
  • [Journal-full-title] Archives of pediatrics & adolescent medicine
  • [ISO-abbreviation] Arch Pediatr Adolesc Med
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00568217
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Placebos; 0 / Suppositories; 144O8QL0L1 / Diclofenac; 362O9ITL9D / Acetaminophen; WK2XYI10QM / Ibuprofen
  •  go-up   go-down


44. Alexy U, Schaefer A, Sailer O, Busch-Stockfisch M, Reinehr T, Kunert J, Kersting M: Sensory preferences and discrimination ability of children before and after an obesity intervention. Int J Pediatr Obes; 2010;5(1):116-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensory preferences and discrimination ability of children before and after an obesity intervention.
  • Sensory preferences and discrimination ability were assessed before and after participating in a long-term outpatient obesity lifestyle intervention for obese children and adolescents ('Obeldicks').
  • Each subject (N=72; 7-16 years) performed 9 experimental sensory tests (5 paired-comparison preference tests, 4 paired-comparison sensitivity tests).
  • For the examination of the taste categories sweet, salty and sour, sugar, table salt or citric acid were added to suitable customary foods.
  • Fatty foods were included in the tests using cheese and sausage (salami) in the preference tests and milk with different fat content in the sensitivity tests.
  • All tests were conducted at the start of the intervention program, after three and twelve months.
  • For both preference and sensitivity tests, there was no significant difference in experimental test decisions between the three time points.
  • [MeSH-major] Adolescent Behavior. Child Behavior. Discrimination (Psychology). Food Preferences. Obesity / therapy. Risk Reduction Behavior. Taste
  • [MeSH-minor] Adolescent. Ambulatory Care. Child. Combined Modality Therapy. Female. Germany. Humans. Male. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19657860.001).
  • [ISSN] 1747-7174
  • [Journal-full-title] International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity
  • [ISO-abbreviation] Int J Pediatr Obes
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Lauronen J, Pakarinen MP, Halttunen J, Kuusanmäki P, Haglund C, Paavonen T: Mucosal expression of p21, p27, p53, Bcl-2, and bax after small bowel resection and autotransplantation in pigs. Pediatr Surg Int; 2005 May;21(5):351-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal expression of p21, p27, p53, Bcl-2, and bax after small bowel resection and autotransplantation in pigs.
  • Massive small bowel resection increases ileal villus height as part of normal adaptation.
  • However, despite no gut loss, autotransplantation of the entire small intestine also increases ileal villus height.
  • Our aim was to test whether similar modulation of enterocyte proliferation and apoptosis underpin these comparable increases in villus height.
  • Fifteen pigs were randomly assigned for laparotomy (n=5), 75% proximal small bowel resection (n=5), or jejunoileal autotransplantation (n=5).
  • Eight weeks postoperatively, full-thickness small bowel sections underwent routine immunohistochemistry for cell cycle inhibitors (p53, p21, and p27), antiapoptotic Bcl-2, and proapoptotic bax.
  • The specimens were analyzed semiquantitatively, and the number of intensively positive epithelial cells for each group was compared from 20 digital images (0.32 mm(2)/image).
  • Compared with laparotomy, small bowel resection decreased the number of p27-positive enterocytes in both jejunum and ileum, increased the number of bax-expressing cells in ileum, but decreased the number of bax-expressing cells in jejunum.
  • In contrast, compared with laparotomy, jejunoileal autotransplantation altered neither mucosal bax nor p27 expression.
  • In all groups, Bcl-2 expression was similarly confined to inflammatory cells of the lamina propria, while both p53 and p21 were negative.
  • We conclude that long-term alterations in the enterocytic expression of certain cell cycle and apoptosis markers (p27 and bax) accompany small bowel resection.
  • These changes differ between the jejunum and the ileum and are not seen after whole small bowel autotransplantation.
  • Therefore, increased ileal villus height after autotransplantation, despite resembling postresectional intestinal adaptation, is underpinned by different regulation of enterocyte proliferation and apoptosis.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Ileum / transplantation. Intestinal Mucosa / metabolism. Intestine, Small / surgery. Jejunum / transplantation. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Apoptosis. Cyclin-Dependent Kinase Inhibitor p21. Cyclin-Dependent Kinase Inhibitor p27. Female. Immunohistochemistry. Random Allocation. Statistics, Nonparametric. Swine. Transplantation, Autologous. bcl-2-Associated X Protein

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Res. 2000 May 1;90(1):45-50 [10781374.001]
  • [Cites] J Pediatr Surg. 2000 Jan;35(1):20-4 [10646767.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1101-5 [10613343.001]
  • [Cites] J Surg Res. 1999 Jun 15;84(2):218-22 [10357923.001]
  • [Cites] Dig Dis Sci. 2001 Mar;46(3):476-85 [11318518.001]
  • [Cites] J Am Coll Surg. 1996 Nov;183(5):441-9 [8912612.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] J Surg Res. 2002 Mar;103(1):37-40 [11855915.001]
  • [Cites] Am J Physiol. 1999 Sep;277(3 Pt 1):G717-24 [10484399.001]
  • [Cites] J Pediatr Surg. 2003 Jun;38(6):875-80 [12778384.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1415-30 [11073801.001]
  • [Cites] Gastroenterology. 1977 Apr;72(4 Pt 1):701-5 [838225.001]
  • [Cites] Surgery. 2000 Aug;128(2):165-70 [10922987.001]
  • [Cites] J Pediatr Surg. 1996 May;31(5):686-94 [8861482.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):899-909 [9736038.001]
  • [Cites] N Engl J Med. 1978 Jun 22;298(25):1393-402 [418341.001]
  • [Cites] J Gastrointest Surg. 1998 Jan-Feb;2(1):44-9 [9841967.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):93-100 [10631368.001]
  • [Cites] Nature. 1996 Jun 20;381(6584):643-4 [8649505.001]
  • [Cites] Transplantation. 2001 Jun 27;71(12):1718-24 [11455248.001]
  • [Cites] Gastroenterology. 1977 Apr;72(4 Pt 1):692-700 [838224.001]
  • [Cites] Scand J Gastroenterol. 1998 Feb;33(2):152-8 [9517525.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • (PMID = 15827752.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


46. Guran T, Turan S, Karadag B, Ersu R, Karakoc F, Bereket A, Dagli E: Bone mineral density in children with non-cystic fibrosis bronchiectasis. Respiration; 2008;75(4):432-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone mineral density in children with non-cystic fibrosis bronchiectasis.
  • Although children with non-CF bronchiectasis have similar risk factors for osteopenia/osteoporosis, data on BMD in this group of patients are lacking.
  • OBJECTIVE: To evaluate BMD in children with non-CF bronchiectasis.
  • METHODS: In this study, we evaluated BMD of the radius and tibia in 32 children (17 girls) with non-CF bronchiectasis and in 23 healthy controls matched for age, sex and pubertal stage by quantitative ultrasound (speed of sound).
  • However, more children with non-CF bronchiectasis had osteopenia (z-scores between -1 and -2 SD) and osteoporosis (z-score <or=2 SD) compared to the control group (62 vs. 30%, p = 0.019).
  • CONCLUSION: Osteopenia is more common in children with non-CF bronchiectasis compared to controls and the risk of osteoporosis and osteopenia increases with age.


47. Harrison AN, Regelmann WE, Zirbes JM, Milla CE: Longitudinal assessment of lung function from infancy to childhood in patients with cystic fibrosis. Pediatr Pulmonol; 2009 Apr;44(4):330-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal assessment of lung function from infancy to childhood in patients with cystic fibrosis.
  • We hypothesized that measures of airflow obstruction by IPFT would correlate strongly with lung function by conventional spirometry later in childhood.


48. Jiang YF, Wang WW, Ye WL, Ni YF, Li J, Chen XL, Jin SW, Lian QQ: [Effects of alprostadil and ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass in pediatric patients with congenital heart diseases]. Zhonghua Yi Xue Za Zhi; 2008 Nov 11;88(41):2893-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of alprostadil and ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass in pediatric patients with congenital heart diseases].
  • OBJECTIVE: To investigate the therapeutic effects of alprostadil (Lipo-PGE1) and Ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass (CPB) in pediatric patients with congenital heart diseases.
  • [MeSH-major] Acute-Phase Reaction / prevention & control. Alprostadil / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Cardiopulmonary Bypass. Glycoproteins / therapeutic use. Lung Injury / prevention & control

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080093.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Cytokines; 0 / Glycoproteins; 80449-32-7 / urinastatin; F5TD010360 / Alprostadil
  •  go-up   go-down


49. Rohlman DS, Bodner T, Arcury TA, Quandt SA, McCauley L: Developing methods for assessing neurotoxic effects in Hispanic non-English speaking children. Neurotoxicology; 2007 Mar;28(2):240-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developing methods for assessing neurotoxic effects in Hispanic non-English speaking children.
  • We have developed a battery to assess neurobehavioral performance in non-English speaking Hispanic children ages 4 years and older.
  • The battery consists of computerized tests from the Behavioral Assessment and Research System, tests selected from the Pediatric Environmental Neurobehavioral Test Battery, and the Object Memory Test.
  • This study has demonstrated the utility of using this test battery to assess cognitive and motor performance in non-English speaking Hispanic children.

  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16759705.001).
  • [ISSN] 0161-813X
  • [Journal-full-title] Neurotoxicology
  • [ISO-abbreviation] Neurotoxicology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Environmental Pollutants
  •  go-up   go-down


50. Wogelius P, Haubek D, Nechifor A, Nørgaard M, Tvedebrink T, Poulsen S: Association between use of asthma drugs and prevalence of demarcated opacities in permanent first molars in 6-to-8-year-old Danish children. Community Dent Oral Epidemiol; 2010 Apr;38(2):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between use of asthma drugs and prevalence of demarcated opacities in permanent first molars in 6-to-8-year-old Danish children.
  • OBJECTIVES: Demarcated opacities in permanent first molars are common developmental tooth defects, characterized by areas with insufficient mineralization of the enamel.
  • The defects present clinically as a continuum from creamy-white demarcated opacities, yellowish-brown demarcated opacities to macroscopic loss of tooth substance.
  • The etiology is sparsely elucidated, but asthma drugs have been suspected to increase the prevalence.
  • The aim of this study was to examine the prevalence of demarcated opacities in permanent first molars among 6-to-8-year-old children with prescriptions and without prescriptions for asthma drugs.
  • METHODS: In a cross-sectional study in two Danish municipalities, all children aged 6-8 years (n = 891) were included.
  • A total of 745 (83.6%) went through a dental examination during which demarcated opacities and tooth substance loss due to these were recorded.
  • The analyses were restricted to 647 children in whom all four permanent first molars had erupted.
  • Data on use of asthma drugs from birth until the time of the dental examination were obtained from a population-based pharmaco-epidemiological prescription database.
  • RESULTS: Among 47 children with prescriptions for both inhaled beta(2)-agonists and inhaled corticosteroids before the age of 3 years, 15 (31.9%) had demarcated opacities of any type, and six children (12.8%) had opacity-related loss of tooth substance.
  • Among 264 children with no prescriptions for either inhaled or oral asthma drugs from birth until the date of the dental examination, 96 (36.4%) had demarcated opacities of any type, and 13 (4.9%) had opacity-related loss of tooth substance.
  • The odds ratio (OR) of any demarcated opacity, and of opacity-related loss of tooth substance in children with prescriptions for both inhaled beta(2)-agonists and inhaled corticosteroids before the age of 3 years was 0.82 (95% CI: 0.39-1.65), and 2.42 (95% CI: 0.70-7.43).
  • CONCLUSIONS: Children with prescriptions for inhaled asthma drugs before the age of 3 years did not have an overall increased risk of demarcated opacities in first permanent molar but they seemed to have an increased risk of the severe demarcated opacities, i.e. opacities resulting in macroscopic loss of tooth substance, and possibly a need for restorative care.
  • [MeSH-major] Anti-Asthmatic Agents / adverse effects. Dental Enamel Hypoplasia / chemically induced. Molar / pathology
  • [MeSH-minor] Adrenergic beta-Agonists / adverse effects. Child. Child, Preschool. Databases, Factual. Denmark. Dental Enamel / pathology. Dentition, Permanent. Drug Information Services. Female. Glucocorticoids / adverse effects. Humans. Male. Odds Ratio

  • Genetic Alliance. consumer health - Asthma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20059490.001).
  • [ISSN] 1600-0528
  • [Journal-full-title] Community dentistry and oral epidemiology
  • [ISO-abbreviation] Community Dent Oral Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Anti-Asthmatic Agents; 0 / Glucocorticoids
  •  go-up   go-down


51. Haberler C, Laggner U, Slavc I, Czech T, Ambros IM, Ambros PF, Budka H, Hainfellner JA: Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol; 2006 Nov;30(11):1462-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype.
  • Immunohistochemical lack of nuclear INI1 protein expression has been recently described as characteristic finding in atypical teratoid/rhabdoid tumors (AT/RTs), and has been suggested as useful marker to distinguish AT/RTs from other malignant pediatric central nervous system (CNS) tumors.
  • In this study, we examined a large series of malignant pediatric CNS tumors to determine the immunohistochemical expression of INI1 protein in different malignant pediatric tumor entities.
  • Archival paraffin-embedded biopsy specimens of 289 malignant pediatric CNS tumors including medulloblastomas, supratentorial primitive neuroectodermal tumors, glioblastomas, anaplastic astrocytomas, anaplastic ependymomas, choroid plexus carcinomas, germ cell tumors, and AT/RTs were analyzed immunohistochemically for expression of nuclear INI1 protein.
  • We conclude that INI1 protein analysis should be routinely performed in all malignant pediatric embryonal CNS tumors to detect cases with lack of INI1 protein, because patients with these tumors are likely to benefit from intensified treatment.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Chromosomal Proteins, Non-Histone / metabolism. DNA-Binding Proteins / metabolism. Neuroectodermal Tumors, Primitive / metabolism. Rhabdoid Tumor / metabolism. Teratoma / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17063089.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


52. Kaufman BD, Auerbach S, Reddy S, Manlhiot C, Deng L, Prakash A, Printz BF, Gruber D, Papavassiliou DP, Hsu DT, Sehnert AJ, Chung WK, Mital S: RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy. Hum Genet; 2007 Dec;122(5):515-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy.

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Hypertrophic Cardiomyopathy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Cardiol. 2005 Aug 2;46(3):470-6 [16053960.001]
  • [Cites] Science. 1998 Jul 17;281(5375):363, 365 [9705713.001]
  • [Cites] Eur J Clin Invest. 2001 Oct;31(10):836-42 [11737220.001]
  • [Cites] J Mol Cell Cardiol. 1991 May;23(5):563-72 [1886136.001]
  • [Cites] Curr Opin Cardiol. 2005 May;20(3):175-81 [15861004.001]
  • [Cites] Circulation. 2007 Feb 13;115(6):773-81 [17261650.001]
  • [Cites] J Am Soc Echocardiogr. 2006 Jun;19(6):788-95 [16762758.001]
  • [Cites] Cardiovasc Drugs Ther. 2005 Jan;19(1):77-87 [15883759.001]
  • [Cites] Med Clin (Barc). 1999 Jul 10;113(5):161-3 [10480137.001]
  • [Cites] Circulation. 1978 Dec;58(6):1072-83 [709763.001]
  • [Cites] Heart Fail Rev. 2005 Sep;10(3):237-48 [16416046.001]
  • [Cites] Pediatr Clin North Am. 2004 Oct;51(5):1305-46 [15331286.001]
  • [Cites] N Engl J Med. 2003 Jan 23;348(4):295-303 [12540642.001]
  • [Cites] J Hypertens. 2002 Apr;20(4):657-63 [11910301.001]
  • [Cites] Circulation. 1995 Aug 15;92 (4):785-9 [7641357.001]
  • [Cites] Pharmacol Rev. 2000 Mar;52(1):11-34 [10699153.001]
  • [Cites] Heart. 2002 Mar;87(3):270-5 [11847170.001]
  • [Cites] J Am Coll Cardiol. 2000 Dec;36(7):2212-8 [11127463.001]
  • [Cites] Hypertension. 1998 Nov;32(5):825-30 [9822439.001]
  • [Cites] Mol Cell Endocrinol. 2004 Mar 31;217(1-2):213-9 [15134820.001]
  • [Cites] Circulation. 1995 Oct 1;92 (7):1808-12 [7671365.001]
  • [Cites] J Am Coll Cardiol. 2004 Nov 16;44(10):2019-26 [15542286.001]
  • [Cites] Am J Cardiol. 1996 Aug 1;78(3):362-4 [8759823.001]
  • [Cites] Hypertension. 2000 Feb;35(2):580-6 [10679501.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2006 Dec;374(3):153-62 [17075718.001]
  • [Cites] Eur Heart J. 2005 Nov;26(22):2457-62 [16087648.001]
  • [Cites] N Engl J Med. 2000 Jun 15;342(24):1778-85 [10853000.001]
  • (PMID = 17851694.001).
  • [ISSN] 1432-1203
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / K08 HL04068; United States / NCRR NIH HHS / RR / RR00645-GCRC
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


53. Iruloh CG, D'Souza SW, Fergusson WD, Baker PN, Sibley CP, Glazier JD: Amino acid transport systems beta and A in fetal T lymphocytes in intrauterine growth restriction and with tumor necrosis factor-alpha treatment. Pediatr Res; 2009 Jan;65(1):51-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amino acid transport systems beta and A in fetal T lymphocytes in intrauterine growth restriction and with tumor necrosis factor-alpha treatment.
  • Intrauterine growth restriction (IUGR) is associated with reduced activity of placental amino acid transport systems beta and A.
  • Whether this phenotype is maintained in fetal cells outside the placenta is unknown.
  • In IUGR, cord blood tumor necrosis factor (TNF)-alpha concentrations are raised, potentially influencing amino acid transport in fetal cells.
  • We used fetal T lymphocytes as a model to study systems beta and A amino acid transporters in IUGR compared with normal pregnancy.
  • We also studied the effect of TNF-alpha on amino acid transporter activity.
  • In fetal lymphocytes from IUGR pregnancies, taurine transporter mRNA expression encoding system beta transporter was reduced, but there was no change in system beta activity.
  • No significant differences were observed in system A mRNA expression (encoding SNAT1 and SNAT2) or system A activity between the two groups.
  • After 24 or 48 h TNF-alpha treatment, fetal T lymphocytes from normal pregnancies showed no significant change in system A or system beta activity, although cell viability was compromised.
  • This study represents the first characterization of amino acid transport in a fetal cell outside the placenta in IUGR.
  • We conclude that the reduced amino acid transporter activity found in placenta in IUGR is not a feature of all fetal cells.
  • [MeSH-major] Amino Acid Transport System A / metabolism. Fetal Growth Retardation / metabolism. Membrane Glycoproteins / metabolism. Membrane Transport Proteins / metabolism. T-Lymphocytes / metabolism. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Birth Weight. Cell Survival. Cells, Cultured. Female. Fetal Blood / immunology. Fetal Blood / metabolism. Gestational Age. Humans. Infant, Newborn. Male. Pregnancy. RNA, Messenger / metabolism. Recombinant Proteins / metabolism. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Res. 1993 Nov;34(5):661-5 [8284106.001]
  • [Cites] Am J Physiol. 1993 Jul;265(1 Pt 1):E31-5 [8338151.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Oct;104(10):1116-22 [9332987.001]
  • [Cites] Pediatr Res. 1997 Oct;42(4):514-9 [9380446.001]
  • [Cites] Pediatr Res. 1998 Aug;44(2):233-8 [9702920.001]
  • [Cites] Pediatr Res. 1998 Oct;44(4):532-7 [9773842.001]
  • [Cites] Pediatr Res. 2005 Nov;58(5):827-32 [16183820.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Jan;290(1):C305-12 [16148032.001]
  • [Cites] Placenta. 2006 Apr-May;27(4-5):510-6 [16023720.001]
  • [Cites] J Physiol. 2006 Nov 1;576(Pt 3):935-46 [16916910.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C332-41 [16956961.001]
  • [Cites] Clin Sci (Lond). 2007 Jul;113(1):1-13 [17536998.001]
  • [Cites] Biotechnol Bioeng. 2007 Aug 1;97(5):1216-29 [17171720.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 14;273(3):1175-9 [10891391.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 31;1467(1):1-6 [10930503.001]
  • [Cites] Pediatr Res. 2001 Feb;49(2):141-7 [11158505.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2001 Sep;4(5):425-31 [11568505.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jan;282(1):C153-60 [11742808.001]
  • [Cites] FEBS Lett. 2002 Apr 24;517(1-3):92-6 [12062416.001]
  • [Cites] Placenta. 2002 May;23(5):392-9 [12061855.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):945-8 [12087403.001]
  • [Cites] Pediatr Int. 2002 Dec;44(6):590-5 [12421253.001]
  • [Cites] J Neurochem. 2002 Dec;83(5):1188-95 [12437590.001]
  • [Cites] Acta Obstet Gynecol Scand. 2003 Dec;82(12):1099-102 [14616253.001]
  • [Cites] Pflugers Arch. 2004 Feb;447(5):784-95 [12845534.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R886-93 [15166008.001]
  • [Cites] Br Med J (Clin Res Ed). 1985 Sep 28;291(6499):845-8 [3931739.001]
  • [Cites] Acta Paediatr Scand Suppl. 1985;319:143-9 [3914183.001]
  • [Cites] Am J Obstet Gynecol. 1989 Nov;161(5):1219-27 [2589443.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Apr;100(4):342-7 [8494835.001]
  • [Cites] Am J Obstet Gynecol. 1996 May;174(5):1575-83 [9065132.001]
  • (PMID = 18703994.001).
  • [ISSN] 1530-0447
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 071224; United Kingdom / Wellcome Trust / / (071224/Z/03/Z
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Transport System A; 0 / Membrane Glycoproteins; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / SLC38A1 protein, human; 0 / SLC38A2 protein, human; 0 / SLC38A4 protein, human; 0 / Tumor Necrosis Factor-alpha; 148686-53-7 / taurine transporter
  • [Other-IDs] NLM/ PMC3087423; NLM/ UKMS34686
  •  go-up   go-down


54. Snider P, Standley KN, Wang J, Azhar M, Doetschman T, Conway SJ: Origin of cardiac fibroblasts and the role of periostin. Circ Res; 2009 Nov 6;105(10):934-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Origin of cardiac fibroblasts and the role of periostin.
  • Cardiac fibroblasts are the most populous nonmyocyte cell type within the mature heart and are required for extracellular matrix synthesis and deposition, generation of the cardiac skeleton, and to electrically insulate the atria from the ventricles.
  • Significantly, cardiac fibroblasts have also been shown to play an important role in cardiomyocyte growth and expansion of the ventricular chambers during heart development.
  • Although there are currently no cardiac fibroblast-restricted molecular markers, it is generally envisaged that the majority of the cardiac fibroblasts are derived from the proepicardium via epithelial-to-mesenchymal transformation.
  • However, still relatively little is known about when and where the cardiac fibroblasts cells are generated, the lineage of each cell, and how cardiac fibroblasts move to reside in their final position throughout all four cardiac chambers.
  • In this review, we summarize the present understanding regarding the function of Periostin, a useful marker of the noncardiomyocyte lineages, and its role during cardiac morphogenesis.
  • Characterization of the cardiac fibroblast lineage and identification of the signals that maintain, expand and regulate their differentiation will be required to improve our understanding of cardiac function in both normal and pathophysiological states.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1983 Jun 23-29;303(5919):701-4 [6190091.001]
  • [Cites] Circ Res. 1986 Sep;59(3):310-20 [3769149.001]
  • [Cites] Cell. 1988 May 20;53(4):577-87 [3370670.001]
  • [Cites] J Mol Cell Cardiol. 1988 Mar;20(3):267-76 [3398057.001]
  • [Cites] Development. 1988 Apr;102(4):639-55 [3048970.001]
  • [Cites] Dev Biol. 1989 Aug;134(2):392-401 [2744239.001]
  • [Cites] Cell. 1989 Dec 22;59(6):1203-11 [2688898.001]
  • [Cites] Biochem J. 1990 Jan 1;265(1):233-41 [2154182.001]
  • [Cites] Dev Biol. 1991 Mar;144(1):107-18 [1847345.001]
  • [Cites] Blood. 1991 May 15;77(10):2266-71 [1709380.001]
  • [Cites] Development. 1991 Apr;111(4):945-53 [1879363.001]
  • [Cites] Development. 1991 Apr;111(4):955-68 [1879364.001]
  • [Cites] J Cardiovasc Pharmacol. 1992;20 Suppl 1:S41-7 [1380618.001]
  • [Cites] J Cell Biol. 1992 Dec;119(5):1361-70 [1447306.001]
  • [Cites] Eur Heart J. 1992 Nov;13 Suppl E:7-14 [1478214.001]
  • [Cites] Pathol Biol (Paris). 1992 Nov;40(9):851-8 [1296156.001]
  • [Cites] Dev Dyn. 1992 Oct;195(2):113-20 [1297453.001]
  • [Cites] Basic Res Cardiol. 1992;87 Suppl 2:183-9 [1299209.001]
  • [Cites] Circ Res. 1994 Feb;74(2):291-8 [8293568.001]
  • [Cites] Biochim Biophys Acta. 1994 Jan 11;1204(1):61-7 [8305476.001]
  • [Cites] Development. 1993 Dec;119(4):1175-86 [8306881.001]
  • [Cites] Cell Adhes Commun. 1994 Apr;2(1):27-43 [7526952.001]
  • [Cites] Exp Physiol. 1994 Nov;79(6):943-56 [7873162.001]
  • [Cites] Dev Biol. 1995 May;169(1):347-58 [7750650.001]
  • [Cites] Development. 1995 Feb;121(2):489-503 [7539357.001]
  • [Cites] Development. 1995 Feb;121(2):549-60 [7539359.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):393-405 [7615639.001]
  • [Cites] J Cell Biol. 1995 Aug;130(3):503-6 [7542656.001]
  • [Cites] Int J Dev Biol. 1995 Jun;39(3):443-57 [7577435.001]
  • [Cites] Cell Adhes Commun. 1995 May;3(2):115-30 [7583005.001]
  • [Cites] Development. 1999 Dec;126(24):5771-83 [10572052.001]
  • [Cites] Development. 2000 Apr;127(8):1607-16 [10725237.001]
  • [Cites] FASEB J. 2000 Apr;14(5):752-60 [10744631.001]
  • [Cites] Cardiovasc Res. 2000 May;46(2):257-63 [10773229.001]
  • [Cites] Cardiovasc Res. 2000 May;46(2):307-15 [10773235.001]
  • [Cites] Cell. 2000 Jun 23;101(7):729-39 [10892744.001]
  • [Cites] Mol Genet Metab. 2000 Sep-Oct;71(1-2):418-35 [11001836.001]
  • [Cites] Circ Res. 2000 Nov 24;87(11):969-71 [11090540.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6576-81 [11108717.001]
  • [Cites] Mech Dev. 2001 May;103(1-2):183-8 [11335131.001]
  • [Cites] Circulation. 2001 Jun 5;103(22):2745-52 [11390347.001]
  • [Cites] Dev Biol. 2001 Sep 1;237(1):116-29 [11518510.001]
  • [Cites] Cell Tissue Res. 2001 Oct;306(1):107-16 [11683172.001]
  • [Cites] Dev Dyn. 2005 Aug;233(4):1454-63 [15977171.001]
  • [Cites] Microsc Microanal. 2005 Jun;11(3):260-7 [16060979.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H982-91 [15849235.001]
  • [Cites] J Cell Sci. 2005 Oct 15;118(Pt 20):4731-9 [16188933.001]
  • [Cites] J Electrocardiol. 2005 Oct;38(4 Suppl):45-50 [16226073.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(24):11131-44 [16314533.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18455-60 [16352730.001]
  • [Cites] J Appl Physiol (1985). 2006 Feb;100(2):564-71 [16223981.001]
  • [Cites] Dev Dyn. 2006 Mar;235(3):759-67 [16450386.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 14;342(3):766-72 [16497272.001]
  • [Cites] Circ Res. 2006 Mar 31;98(6):801-10 [16484613.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Ann Anat. 2006 May;188(3):199-212 [16711159.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19700-8 [16702213.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1015-26 [16617141.001]
  • [Cites] Atherosclerosis. 2006 Oct;188(2):292-300 [16325820.001]
  • [Cites] Cell. 2006 Sep 22;126(6):1037-48 [16990131.001]
  • [Cites] Ann N Y Acad Sci. 2006 Oct;1080:76-84 [17132776.001]
  • [Cites] Dev Biol. 2007 Feb 1;302(1):256-66 [17070513.001]
  • [Cites] Nat Med. 2007 Feb;13(2):204-10 [17237794.001]
  • [Cites] Reproduction. 2007 Feb;133(2):405-14 [17307908.001]
  • [Cites] Semin Cell Dev Biol. 2007 Feb;18(1):67-76 [17276708.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2082-94 [17043657.001]
  • [Cites] Cardiovasc Res. 2007 May 1;74(2):184-95 [17109837.001]
  • [Cites] J Cell Biochem. 2007 Jun 1;101(3):695-711 [17226767.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 May;292(5):C1799-808 [17229813.001]
  • [Cites] Hypertension. 2007 Jun;49(6):1409-14 [17485602.001]
  • [Cites] ScientificWorldJournal. 2007;7:1090-113 [17619792.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2007 Aug 29;362(1484):1437-43 [17569642.001]
  • [Cites] Circ Res. 2007 Aug 3;101(3):313-21 [17569887.001]
  • [Cites] Dev Cell. 2001 Sep;1(3):435-40 [11702954.001]
  • [Cites] Hypertension. 2002 Feb;39(2):258-63 [11847194.001]
  • [Cites] Circ Res. 2002 Mar 22;90(5):520-30 [11909815.001]
  • [Cites] Cardiovasc Pathol. 2002 Mar-Apr;11(2):78-87 [11934598.001]
  • [Cites] Dev Biol. 2002 Aug 1;248(1):170-81 [12142029.001]
  • [Cites] Hypertension. 2002 Aug;40(2):148-54 [12154105.001]
  • [Cites] Anat Rec. 2002 Sep 1;268(1):27-37 [12209562.001]
  • [Cites] Curr Opin Cell Biol. 2002 Oct;14(5):608-16 [12231357.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5358-64 [12235007.001]
  • [Cites] Circ Res. 2002 Sep 20;91(6):532-9 [12242272.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12877-82 [12297622.001]
  • [Cites] Anat Embryol (Berl). 2002 Dec;206(1-2):73-83 [12478370.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Feb;35(2):113-8 [12479860.001]
  • [Cites] Int J Dev Biol. 2002 Dec;46(8):1005-13 [12533024.001]
  • [Cites] Circ Res. 2003 Apr 18;92(7):749-56 [12637368.001]
  • [Cites] Circ Res. 2003 Jun 13;92(11):1217-24 [12730096.001]
  • [Cites] Histochem Cell Biol. 2003 Aug;120(2):103-10 [12883905.001]
  • [Cites] Physiol Genomics. 2003 Aug 15;14(3):261-71 [12799472.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Oct;14(5):391-407 [12948523.001]
  • [Cites] Circ Res. 2003 Sep 5;93(5):421-8 [12893743.001]
  • [Cites] Physiol Genomics. 2003 Nov 11;15(3):165-76 [14612588.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2004 Jan;276(1):43-57 [14699633.001]
  • [Cites] Circ Res. 2004 Apr 2;94(6):828-35 [14976125.001]
  • [Cites] Cardiovasc Res. 2004 Aug 1;63(2):236-44 [15249181.001]
  • [Cites] Dev Dyn. 2004 Aug;230(4):787-94 [15254913.001]
  • [Cites] J Cell Physiol. 2004 Sep;200(3):377-86 [15254965.001]
  • [Cites] Cardiovasc Res. 2004 Aug 15;63(3):423-32 [15276467.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12573-8 [15310850.001]
  • [Cites] Cardiovasc Res. 2004 Oct 1;64(1):24-31 [15364610.001]
  • [Cites] Circ Res. 2004 Sep 17;95(6):645-54 [15297379.001]
  • [Cites] Cardiovasc Res. 2004 Nov 1;64(2):195-7 [15485677.001]
  • [Cites] Circ Res. 1974 Aug;35(2):suppl II:17-26 [4276486.001]
  • [Cites] Exp Cell Res. 1976 Dec;103(2):321-30 [1001365.001]
  • [Cites] Cytobios. 1980;28(109):41-61 [7428441.001]
  • [Cites] Circ Res. 2007 Aug 3;101(3):230-1 [17673682.001]
  • [Cites] Nat Med. 2007 Aug;13(8):962-9 [17632525.001]
  • [Cites] Nat Med. 2007 Aug;13(8):952-61 [17660828.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1883-91 [17604329.001]
  • [Cites] Development. 2007 Oct;134(20):3627-37 [17855432.001]
  • [Cites] Am J Pathol. 2007 Nov;171(5):1407-18 [17823281.001]
  • [Cites] Adv Drug Deliv Rev. 2007 Nov 10;59(13):1299-305 [17825456.001]
  • [Cites] ScientificWorldJournal. 2007;7:1777-98 [18040540.001]
  • [Cites] Ann Biomed Eng. 2008 Jan;36(1):41-56 [17999190.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):295-303 [18208976.001]
  • [Cites] Dev Dyn. 2008 Mar;237(3):847-57 [18265012.001]
  • [Cites] J Biol Chem. 2008 Mar 14;283(11):6861-8 [18201965.001]
  • [Cites] Ann N Y Acad Sci. 2008 Mar;1123:30-40 [18375575.001]
  • [Cites] Circulation. 2008 Apr 1;117(13):1630-41 [18347210.001]
  • [Cites] Circ Res. 2008 Apr 11;102(7):752-60 [18296617.001]
  • [Cites] Nature. 2008 Jul 3;454(7200):104-8 [18480752.001]
  • [Cites] Nature. 2008 Jul 3;454(7200):109-13 [18568026.001]
  • [Cites] J Periodontol. 2008 Aug;79(8):1480-90 [18672999.001]
  • [Cites] Br J Cancer. 2008 Nov 4;99(9):1375-9 [18797460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17824-9 [19004760.001]
  • [Cites] Circ Res. 2009 Jan 2;104(1):113-23 [19023134.001]
  • [Cites] Circ Res. 2009 Jan 2;104(1):e1-7 [19038863.001]
  • [Cites] Dev Dyn. 2009 Feb;238(2):431-42 [19161227.001]
  • [Cites] J Cell Biol. 2009 Feb 9;184(3):357-64 [19188493.001]
  • [Cites] Dev Cell. 2009 Feb;16(2):161-2 [19217417.001]
  • [Cites] Dev Cell. 2009 Feb;16(2):233-44 [19217425.001]
  • [Cites] Nature. 2009 Apr 16;458(7240):E8-9; discussion E9-10 [19369973.001]
  • [Cites] Cancer Lett. 2009 Aug 28;281(2):213-9 [19328625.001]
  • [Cites] Heart. 2009 Oct;95(19):1561-6 [19224905.001]
  • [Cites] Anat Rec (Hoboken). 2010 May;293(5):762-9 [19479965.001]
  • [Cites] J Mol Med (Berl). 1995 Jul;73(7):333-46 [8520966.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):409-14 [7493021.001]
  • [Cites] Dev Dyn. 1995 Sep;204(1):41-7 [8563024.001]
  • [Cites] J Cardiovasc Electrophysiol. 1995 Oct;6(10 Pt 1):813-22 [8542077.001]
  • [Cites] J Mol Cell Cardiol. 1995 Jun;27(6):1281-92 [8531210.001]
  • [Cites] Dev Biol. 1996 Mar 15;174(2):221-32 [8631495.001]
  • [Cites] Can J Cardiol. 1996 Mar;12(3):231-6 [8624972.001]
  • [Cites] Histol Histopathol. 1996 Jan;11(1):175-80 [8720462.001]
  • [Cites] Am J Physiol. 1996 Nov;271(5 Pt 2):H2183-9 [8945939.001]
  • [Cites] Dev Dyn. 1997 Feb;208(2):244-54 [9022061.001]
  • [Cites] Acta Anat (Basel). 1996;156(3):173-86 [9124035.001]
  • [Cites] Int J Biochem Cell Biol. 1997 Jan;29(1):31-42 [9076939.001]
  • [Cites] Dev Genet. 1997;20(2):119-32 [9144923.001]
  • [Cites] Circ Res. 1997 Sep;81(3):423-37 [9285645.001]
  • [Cites] Dev Biol. 1998 Jan 15;193(2):169-81 [9473322.001]
  • [Cites] Mech Dev. 1998 Apr;73(1):23-32 [9545521.001]
  • [Cites] Cell Tissue Res. 1998 May;292(2):325-32 [9560475.001]
  • [Cites] Circ Res. 1998 Jun 1;82(10):1043-52 [9622157.001]
  • [Cites] Dev Biol. 1998 Jun 1;198(1):32-44 [9640330.001]
  • [Cites] Virchows Arch. 1998 May;432(5):461-8 [9645447.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):20383-9 [9685391.001]
  • [Cites] Dev Dyn. 1998 Sep;213(1):105-13 [9733105.001]
  • [Cites] Physiol Rev. 1999 Jan;79(1):215-62 [9922372.001]
  • [Cites] Development. 1999 May;126(9):1845-57 [10101119.001]
  • [Cites] Wound Repair Regen. 1999 Jan-Feb;7(1):26-35 [10231503.001]
  • [Cites] Circ Res. 1999 Jun 25;84(12):1365-79 [10381888.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1239-49 [10404027.001]
  • [Cites] Development. 1999 Aug;126(16):3597-605 [10409505.001]
  • [Cites] Am J Physiol. 1999 Jul;277(1 Pt 1):C1-9 [10409103.001]
  • [Cites] Circ Res. 2004 Dec 10;95(12):1167-73 [15539634.001]
  • [Cites] J Exp Med. 2004 Dec 20;200(12):1673-9 [15611293.001]
  • [Cites] Cardiovasc Res. 2005 Jan 1;65(1):40-51 [15621032.001]
  • [Cites] Circ Res. 2005 Mar 18;96(5):526-34 [15705966.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:657-87 [15822192.001]
  • (PMID = 19893021.001).
  • [ISSN] 1524-4571
  • [Journal-full-title] Circulation research
  • [ISO-abbreviation] Circ. Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL085098-029002; United States / NHLBI NIH HHS / HL / R01 HL092508; United States / NHLBI NIH HHS / HL / R01 HL092508-01A1; United States / NHLBI NIH HHS / HL / P01 HL085098; United States / NHLBI NIH HHS / HL / T32 HL079995; None / None / / R01 HL092508-01A1; United States / NHLBI NIH HHS / HL / P01 HL085098-029002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human
  • [Number-of-references] 176
  • [Other-IDs] NLM/ NIHMS158395; NLM/ PMC2786053
  •  go-up   go-down


55. Oztek FZ, Ipsiroglu O, Mueller T, Aufricht C: Outcome after renal transplantation in children from native and immigrant families in Austria. Eur J Pediatr; 2009 Jan;168(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ethnicity affects the transplant survival rates substantially, but there has been no European academic evaluation of the effects of immigration on the pediatric renal transplantation outcome.
  • The aim of this study was to compare the outcomes of renal transplantation between the children of immigrant families and the children of native families at the pediatric nephrology unit of the Medical University of Vienna, Austria.
  • The two groups were also comparable in the rates of acute rejection episodes, 24-h blood pressure, and growth velocity.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplant Proc. 1977 Mar;9(1):137-42 [325754.001]
  • [Cites] Pediatr Transplant. 2000 Aug;4(3):221-34 [10933324.001]
  • [Cites] Am J Transplant. 2005 Nov;5(11):2682-7 [16212627.001]
  • [Cites] N Engl J Med. 1992 Sep 17;327(12):840-5 [1508243.001]
  • [Cites] Pediatr Transplant. 2000 Aug;4(3):235-46 [10933325.001]
  • [Cites] Pediatr Nephrol. 1998 Sep;12(7):534-9 [9761350.001]
  • [Cites] Liver Transpl. 2003 Mar;9(3):254-9 [12619022.001]
  • [Cites] J Adolesc Health. 2007 Oct;41(4):343-9 [17875459.001]
  • [Cites] Pediatr Nephrol. 2004 Dec;19(12):1385-9 [15517413.001]
  • [Cites] Transplantation. 1993 Dec;56(6):1381-4 [8279007.001]
  • [Cites] J Adolesc Health. 2007 Oct;41(4):319-20 [17875455.001]
  • [Cites] N Engl J Med. 1978 Oct 12;299(15):793-8 [151230.001]
  • [Cites] Wien Klin Wochenschr. 2005 Aug;117(15-16):541-7 [16158204.001]
  • [Cites] Pediatrics. 2003 Aug;112(2):409-11 [12897294.001]
  • [Cites] PLoS Med. 2006 Oct;3(10):e294 [17076546.001]
  • [Cites] Transplant Proc. 2005 Mar;37(2):699-700 [15848506.001]
  • [Cites] Lancet. 2006 Feb 11;367(9509):525-7 [16473128.001]
  • [Cites] N Engl J Med. 1991 Jan 31;324(5):302-7 [1898431.001]
  • [Cites] J Pediatr. 1997 Mar;130(3):455-62 [9063424.001]
  • [Cites] Eur J Pediatr. 1996 May;155(5):351-6 [8741029.001]
  • [Cites] Pediatrics. 1993 Dec;92(6):876-8 [8233757.001]
  • [Cites] Transpl Int. 1999;12(2):135-40 [10363596.001]
  • [Cites] Pediatr Nephrol. 2001 Aug;16(8):613-7 [11519888.001]
  • [Cites] Kidney Int Suppl. 1985 Dec;17:S15-7 [3912583.001]
  • (PMID = 18351389.001).
  • [ISSN] 1432-1076
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


56. Saewyc EM, Bearinger LH, McMahon G, Evans T: A national needs assessment of nurses providing health care to adolescents. J Prof Nurs; 2006 Sep-Oct;22(5):304-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A national survey of nurse members of the American Public Health Association, the National Association of Pediatric Nurse Associates and Practitioners, and the National Association of School Nurses was conducted in 1997 (n = 520) and was compared with findings from a parallel survey conducted in 1985 that assessed perceived competence in addressing common adolescent health issues, relevance of those issues to nurses' practice, and leadership skills.

  • MedlinePlus Health Information. consumer health - Teen Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990122.001).
  • [ISSN] 8755-7223
  • [Journal-full-title] Journal of professional nursing : official journal of the American Association of Colleges of Nursing
  • [ISO-abbreviation] J Prof Nurs
  • [Language] eng
  • [Grant] United States / PHS HHS / / 448-CCU513331; United States / PHS HHS / / MCJ00985; United States / PHS HHS / / MCJ273A03-03-0
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


57. Biederman J, Petty CR, Monuteaux MC, Fried R, Byrne D, Mirto T, Spencer T, Wilens TE, Faraone SV: Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry; 2010 Apr;167(4):409-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: The authors conducted a longitudinal case-control study of 6- to 18-year-old girls with (N=140) and without (N=122) ADHD ascertained from psychiatric and pediatric sources.


58. Youngstrom E, Meyers O, Youngstrom JK, Calabrese JR, Findling RL: Comparing the effects of sampling designs on the diagnostic accuracy of eight promising screening algorithms for pediatric bipolar disorder. Biol Psychiatry; 2006 Nov 1;60(9):1013-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing the effects of sampling designs on the diagnostic accuracy of eight promising screening algorithms for pediatric bipolar disorder.
  • CONCLUSIONS: Results indicate that checklists perform less well discriminating pediatric bipolar disorder under conditions that more closely resemble clinical practice.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056395.001).
  • [ISSN] 0006-3223
  • [Journal-full-title] Biological psychiatry
  • [ISO-abbreviation] Biol. Psychiatry
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH066647
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Kanderová V, Hrusák O, Kalina T: Aberrantly expressed CEACAM6 is involved in the signaling leading to apoptosis of acute lymphoblastic leukemia cells. Exp Hematol; 2010 Aug;38(8):653-660.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly expressed CEACAM6 is involved in the signaling leading to apoptosis of acute lymphoblastic leukemia cells.
  • OBJECTIVE: The aberrant expression of myeloid antigens on acute lymphoblastic leukemia (ALL) cells is a well-documented phenomenon.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Neoplasm / metabolism. Apoptosis. Cell Adhesion Molecules / metabolism. Gene Expression Regulation, Leukemic. MAP Kinase Signaling System. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20380867.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CEACAM6 protein, human; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins; 0 / Integrins; 126547-89-5 / Intercellular Adhesion Molecule-1; EC 2.7.11.1 / Oncogene Protein v-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


60. Komaki H, Nishigaki Y, Fuku N, Hosoya H, Murayama K, Ohtake A, Goto Y, Wakamoto H, Koga Y, Tanaka M: Pyruvate therapy for Leigh syndrome due to cytochrome c oxidase deficiency. Biochim Biophys Acta; 2010 Mar;1800(3):313-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyruvate therapy for Leigh syndrome due to cytochrome c oxidase deficiency.
  • BACKGROUND: Recently we proposed the therapeutic potential of pyruvate therapy for mitochondrial diseases.
  • Leigh syndrome is a progressive neurodegenerative disorder ascribed to either mitochondrial or nuclear DNA mutations.
  • METHODS: In an attempt to circumvent the mitochondrial dysfunction, we orally applied sodium pyruvate and analyzed its effect on an 11-year-old female with Leigh syndrome due to cytochrome c oxidase deficiency accompanied by cardiomyopathy.
  • The patient was administered sodium pyruvate at a maintenance dose of 0.5 g/kg/day and followed up for 1 year.
  • RESULTS: The exercise intolerance was remarkably improved so that she became capable of running.
  • Echocardiography indicated improvements both in the left ventricle ejection fraction and in the fractional shortening.
  • Electrocardiography demonstrated amelioration of the inverted T waves.
  • When the pyruvate administration was interrupted because of a gastrointestinal infection, the serum lactate level became elevated and the serum pyruvate level, decreased, suggesting that the pyruvate administration was effective in decreasing the lactate-to-pyruvate ratio.
  • CONCLUSIONS: These data indicate that pyruvate therapy was effective in improving exercise intolerance at least in a patient with cytochrome c oxidase deficiency.
  • GENERAL SIGNIFICANCE: Administration of sodium pyruvate may prove effective for other patients with cytochrome c oxidase deficiency due to mitochondrial or nuclear DNA mutations.
  • [MeSH-major] Cytochrome-c Oxidase Deficiency / genetics. Electron Transport Complex IV / genetics. Leigh Disease / drug therapy. Leigh Disease / genetics. Pyruvates / therapeutic use
  • [MeSH-minor] Adult. DNA / genetics. DNA, Mitochondrial / genetics. Female. Humans. Magnetic Resonance Imaging. Mutation. Nystagmus, Pathologic / genetics. Nystagmus, Pathologic / pathology

  • Genetic Alliance. consumer health - C Syndrome.
  • Genetic Alliance. consumer health - Leigh syndrome.
  • Genetic Alliance. consumer health - Mitochondrial complex IV deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19616603.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Pyruvates; 9007-49-2 / DNA; EC 1.9.3.1 / Electron Transport Complex IV
  •  go-up   go-down


61. Lougheed MD, Garvey N, Chapman KR, Cicutto L, Dales R, Day AG, Hopman WM, Lam M, Sears MR, Szpiro K, To T, Paterson NAM: Variations and gaps in management of acute asthma in Ontario emergency departments. Chest; 2009 Mar;135(3):724-736
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations and gaps in management of acute asthma in Ontario emergency departments.
  • BACKGROUND: Variation in hospitalization rates for acute asthma in Ontario may reflect gaps between evidence and current emergency department (ED) management.
  • We investigated ED management of asthma and differences in practice patterns for pediatric (< 20 years old) and adult (> or = 20 years old) patients in Ontario EDs.
  • RESULTS: Reported results are based on the first of 2,671 pediatric (42.0% female) and 2,078 adult (66.7% female) visits with a corresponding questionnaire.
  • Documentation of peak expiratory flow (27.2% of pediatric [age > or = 7] and 44.3% of adult charts), use of systemic steroids in ED (35.2% pediatric and 33.0% adult charts) and on discharge (31.7% pediatric and 33.2% adult charts), and referrals to asthma services (2.8% pediatric and 2.7% adult charts) varied among sites (all p < 0.001).
  • CONCLUSIONS: Knowledge translation initiatives are warranted to increase adherence with best practices in emergency management of asthma (such as objective assessment of airflow rates, use of systemic steroids, and referrals) in order to reduce variations in care and improve outcomes of severe acute asthma.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Anti-Asthmatic Agents / therapeutic use. Child. Child, Preschool. Female. Glucocorticoids / therapeutic use. Guideline Adherence. Hospitalization. Humans. Male. Ontario. Practice Guidelines as Topic. Referral and Consultation

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017869.001).
  • [ISSN] 1931-3543
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Asthmatic Agents; 0 / Glucocorticoids
  •  go-up   go-down


62. Kasamon YL, Jones RJ, Piantadosi S, Ambinder RF, Abrams RA, Borowitz MJ, Morrison C, Smith BD, Flinn IW: High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant; 2005 Feb;11(2):93-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
  • The records of all adult and pediatric non-Hodgkin lymphoma patients receiving BMT at Johns Hopkins from 1980 to 2003 were reviewed, and 37 patients were identified who had CNS involvement that was treated into remission by the time of BMT.
  • The chief histologies were diffuse large B-cell lymphoma and T-cell lymphoblastic lymphoma/leukemia.
  • After BMT, long-term survival is thus achievable in a subset of patients with a history of treated CNS involvement by non-Hodgkin lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682069.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA09071; United States / NCI NIH HHS / CA / CA096888; United States / NCI NIH HHS / CA / R01 CA127574; United States / NCI NIH HHS / CA / CA15396; United States / NCI NIH HHS / CA / R01 CA127574-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


63. Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, Campana D, Koscielniak E, Niemeyer C, Schlegel PG, Müller I, Niethammer D, Bader P: Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol; 2005 Mar;128(6):774-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
  • Minimal (i.e. submicroscopic) residual disease (MRD) predicts outcome in childhood acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Biomarkers, Tumor / analysis. Flow Cytometry / methods. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755280.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


64. Beutel K, Gross-Wieltsch U, Wiesel T, Stadt UZ, Janka G, Wagner HJ: Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatr Blood Cancer; 2009 Aug;53(2):184-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin.

  • Genetic Alliance. consumer health - Hemophagocytic Lymphohistiocytosis (HLH).
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2009 Dec 15;53(7):1359; author reply 1360 [19533652.001]
  • (PMID = 19353621.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


65. Kosulin K, Haberler C, Hainfellner JA, Amann G, Lang S, Lion T: Investigation of adenovirus occurrence in pediatric tumor entities. J Virol; 2007 Jul;81(14):7629-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of adenovirus occurrence in pediatric tumor entities.
  • We have therefore employed a real-time quantitative PCR (RQ-PCR) assay permitting highly sensitive detection of all 51 currently known human AdV serotypes to screen more than 500 tumor specimens derived from 17 different childhood cancer entities including leukemias, lymphomas, and solid tumors.


66. Kato I, Manabe A, Aoyama C, Kamiya T, Morimoto T, Matsufuji H, Suzuki K, Kitagawa Y, Hori T, Tsurusawa M, Kiyokawa N, Junichiro F, Hosoya R: Development of diffuse large B cell lymphoma during the maintenance therapy for B-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Feb;48(2):230-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of diffuse large B cell lymphoma during the maintenance therapy for B-lineage acute lymphoblastic leukemia.
  • Non-Hodgkin lymphoma (NHL) is a very rare complication of acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Lymphoma, B-Cell / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


67. Ketcham AS, Smith JE, Lee FS, Halstead LA, White DR: Clinical course following endoscopic repair of type 1 laryngeal clefts. Int J Pediatr Otorhinolaryngol; 2008 Aug;72(8):1261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The difference in patient age between failures and successes (21.3 months vs. 24.2 months) was non-significant (p=0.661, two-tail t-test).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18584883.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


68. Piercey GE, Gauvreau K, Blume ED, Bastardi HJ, Fynn-Thompson F, Singh TP: Waiting list mortality among children listed for heart transplantation in the United States. Circulation; 2009 Feb 10;119(5):717-727
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined waiting list mortality since the pediatric heart allocation system was revised in 1999 to determine whether the revised allocation system is prioritizing patients optimally and to identify specific high-risk populations that may benefit from emerging pediatric cardiac assist devices.
  • CONCLUSIONS: US waiting list mortality for pediatric heart transplantation remains unacceptably high in the current era.
  • Specific high-risk subgroups can be identified that may benefit from emerging pediatric cardiac assist technologies.
  • The current pediatric heart-allocation system captures medical urgency poorly.
  • Further research is needed to define the optimal organ-allocation system for pediatric heart transplantation.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Transplant. 2006;6(5 Pt 2):1228-42 [16613598.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Feb;131(2):455-61 [16434278.001]
  • [Cites] J Heart Lung Transplant. 2007 Aug;26(8):796-807 [17692783.001]
  • [Cites] Hepatology. 2003 Aug;38(2):460-9 [12883491.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Dec;122(6):1186-95 [11726895.001]
  • [Cites] Chest. 2005 Jul;128(1):407-15 [16002964.001]
  • [Cites] J Heart Lung Transplant. 2007 Oct;26(10):980-5 [17919616.001]
  • [Cites] Circulation. 2006 May 16;113(19):2313-9 [16702487.001]
  • [Cites] N Engl J Med. 2007 Aug 30;357(9):885-96 [17761592.001]
  • [Cites] Prog Pediatr Cardiol. 2000 Jun 1;11(2):99-105 [10856691.001]
  • [Cites] ASAIO J. 2005 Jan-Feb;51(1):4-10 [15745126.001]
  • [Cites] Circulation. 2006 Jan 3;113(1):147-55 [16391168.001]
  • [Cites] J Heart Lung Transplant. 1997 Dec;16(12):1255-66 [9436138.001]
  • [Cites] Transplant Proc. 2004 Dec;36(10):3156-60 [15686717.001]
  • [Cites] Cardiol Young. 2000 Oct;10(4):358-66 [10950333.001]
  • [Cites] Pediatrics. 1976 Aug;58(2):259-63 [951142.001]
  • [Cites] Arch Surg. 2007 Nov;142(11):1079-85 [18025337.001]
  • [Cites] Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2006;:115-22 [16638556.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):793-800 [11248154.001]
  • [Cites] J Heart Lung Transplant. 2007 Jun;26(6):565-71 [17543778.001]
  • [Cites] J Heart Lung Transplant. 1997 Jul;16(7):713-22 [9257253.001]
  • [Cites] ASAIO J. 2005 Sep-Oct;51(5):533-5 [16322713.001]
  • [Cites] Circulation. 2007 Feb 6;115(5):658-76 [17261651.001]
  • [Cites] N Engl J Med. 2008 Aug 14;359(7):709-14 [18703473.001]
  • [Cites] J Am Coll Cardiol. 2007 Sep 25;50(13):1282-90 [17888847.001]
  • [Cites] J Heart Lung Transplant. 2003 Feb;22(2):147-53 [12581762.001]
  • [Cites] Ann Thorac Surg. 1996 Feb;61(2):570-5 [8572769.001]
  • [Cites] J Heart Lung Transplant. 1999 Nov;18(11):1065-70 [10598729.001]
  • [Cites] ASAIO J. 2007 Jan-Feb;53(1):4-7 [17237642.001]
  • [Cites] ASAIO J. 2006 Sep-Oct;52(5):525-9 [16966851.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Jan;135(1):147-55, 155.e1-2 [18179931.001]
  • [Cites] Liver Transpl. 2000 Sep;6(5):543-52 [10980052.001]
  • (PMID = 19171850.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / T32 HL007572; United States / NHLBI NIH HHS / HL / T32 HL00757-24
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS649051; NLM/ PMC4278666
  •  go-up   go-down


69. Perlhagen M, Forsberg T, Perlhagen J, Nivesjö M: Evaluating the specificity of a new type of urine collection bag for infants. J Pediatr Urol; 2007 Oct;3(5):378-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Further studies will be valuable as a specificity of 97.7% suggests that this collection device could give the clinician a non-invasive option for diagnosing UTI in infants.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947777.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Jiménez-Morales S, Miranda-Peralta E, Saldaña-Alvarez Y, Perez-Vera P, Paredes-Aguilera R, Rivera-Luna R, Velázquez-Cruz R, Ramírez-Bello J, Carnevale A, Orozco L: BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients. Leuk Res; 2008 Oct;32(10):1518-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients.
  • This study was conducted to determine the frequency of the most common fusion genes in Mexican pediatric patients with acute lymphoblastic leukemia (ALL).
  • The prevalence of E2A-PBX1 is one of the highest that has been described thus far in childhood ALL.
  • With regards to the immunophenotype, ETV6-RUNX1 was expressed in both pre-B and T-cell cases, while the presence of E2A-PBX1 and BCR-ABL was associated with the pre-B ALL phenotype.
  • The prevalence of E2A-PBX1 in Mexican pediatric cases supports the existence of ethnic differences in the frequency of molecular markers of ALL.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Fusion Proteins, bcr-abl / genetics. Homeodomain Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455790.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins; 146150-85-8 / E2A-Pbx1 fusion protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


71. González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M, International Pediatric Hepatitis C Therapy Group: Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology; 2005 Nov;42(5):1010-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
  • Chronic hepatitis C virus (HCV) infection is usually asymptomatic in children, but significant liver disease may occur.
  • We evaluated the efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic HCV.
  • We determined the optimal ribavirin dose in an initial cohort of a phase 1 study and then subsequently used it, in combination with interferon alfa-2b, in a second cohort of this study and a phase 3 trial.
  • The primary efficacy endpoint in all studies was sustained virological response, defined by undetectable serum HCV RNA 24 weeks after completion of therapy.
  • All efficacy and safety analyses were performed on the intent-to-treat population.
  • Children receiving interferon alfa-2b plus ribavirin 15 mg/kg/d in the phase 1 study had the maximum reduction in serum HCV RNA at treatment weeks 4 and 12 with an acceptable safety profile.
  • This ribavirin dose was selected as optimal and used in all subsequent studies.
  • In all, 46% (54/118) of optimally treated children achieved sustained virological response.
  • Sustained virological response was significantly higher in children with HCV genotype 2/3 (84%) than in those with HCV genotype 1 (36%).
  • Adverse events led to dose modification in 37 (31%) and discontinuation in 8 (7%).
  • Multiple-dose interferon alfa-2b and ribavirin peak and trough concentrations and area-under-the-curve were similar between children and adults.
  • In conclusion, interferon alfa-2b in combination with ribavirin is effective and safe in children with chronic hepatitis C virus.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Ribavirin / therapeutic use
  • [MeSH-minor] Adolescent. Body Height / drug effects. Body Weight / drug effects. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Therapy, Combination. Female. Hepacivirus / genetics. Humans. Male. RNA, Viral / blood. Recombinant Proteins. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16250032.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; 0 / Recombinant Proteins; 49717AWG6K / Ribavirin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


72. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML: Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res; 2009 Mar;33(3):355-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.
  • Juvenile myelomonocytic leukemia (JMML) is an aggressive childhood myeloproliferative disorder characterized by the overproduction of myelomonocytic cells.

  • Genetic Alliance. consumer health - Juvenile Myelomonocytic Leukemia (JMML).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2006 Mar;38(3):294-6 [16474404.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1038-40 [16170316.001]
  • [Cites] Science. 2006 Mar 3;311(5765):1287-90 [16439621.001]
  • [Cites] Am J Hum Genet. 2006 Jul;79(1):129-35 [16773572.001]
  • [Cites] J Cell Biol. 2006 Oct 9;175(1):87-97 [17015617.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):75-9 [17143282.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):70-4 [17143285.001]
  • [Cites] Leukemia. 2007 Mar;21(3):556-60 [17268527.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5477-80 [17332249.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):1013-7 [17603482.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):1007-12 [17603483.001]
  • [Cites] Pediatr Blood Cancer. 2007 Oct 15;49(5):629-33 [16991133.001]
  • [Cites] Blood. 2008 Jan 15;111(2):966-7; author reply 967-8 [18182584.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1124-7 [18000165.001]
  • [Cites] Br J Haematol. 2008 Mar;140(6):610-24 [18302710.001]
  • [Cites] Br J Haematol. 2008 May;141(5):567-75 [18422786.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):335-43 [18835035.001]
  • [Cites] Pediatr Res. 2009 Mar;65(3):334-40 [19047918.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3631-52 [10550163.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):523-7 [10598665.001]
  • [Cites] Blood. 2000 Jan 15;95(2):639-45 [10627474.001]
  • [Cites] Mol Cell. 2000 Jan;5(1):189-95 [10678181.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):465-8 [11704759.001]
  • [Cites] Leukemia. 2002 Apr;16(4):645-9 [11960345.001]
  • [Cites] Am J Hum Genet. 2002 Jun;70(6):1555-63 [11992261.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4147-53 [12010819.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):148-50 [12717436.001]
  • [Cites] J Med Genet. 2003 Sep;40(9):704-8 [12960218.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602 [14699048.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2325-31 [14644997.001]
  • [Cites] Curr Hematol Rep. 2004 May;3(3):203-9 [15087069.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4243-50 [14982883.001]
  • [Cites] Blood. 1974 Mar;43(3):341-50 [4521369.001]
  • [Cites] J Pediatr. 1978 Jun;92(6):925-9 [96239.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6456-61 [3465439.001]
  • [Cites] Blood. 1991 Mar 1;77(5):925-9 [1704804.001]
  • [Cites] Br J Haematol. 1992 Jan;80(1):40-8 [1311195.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1311-8 [1536955.001]
  • [Cites] Cell. 1992 Apr 17;69(2):265-73 [1568246.001]
  • [Cites] Nature. 1992 Apr 23;356(6371):713-5 [1570015.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):597-601 [8302341.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):637-9 [8302348.001]
  • [Cites] Blood. 1994 Nov 15;84(10):3435-9 [7949098.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):137-43 [8563750.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):144-8 [8563751.001]
  • [Cites] Development. 1996 Apr;122(4):1137-46 [8620840.001]
  • [Cites] N Engl J Med. 1997 Jun 12;336(24):1713-20 [9180088.001]
  • [Cites] J Pediatr. 1997 Jun;130(6):885-9 [9202609.001]
  • [Cites] Leuk Res. 1997 Aug;21(8):697-701 [9379676.001]
  • [Cites] J Med Genet. 2004 Nov;41(11):e117 [15520399.001]
  • [Cites] Blood. 2005 Jan 1;105(1):410-9 [15353481.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):179-91 [15710330.001]
  • [Cites] Blood. 2005 Jul 1;106(1):311-7 [15761018.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2183-5 [15928039.001]
  • [Cites] Nat Genet. 2006 Mar;38(3):331-6 [16474405.001]
  • (PMID = 18954903.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5K22CA113577-03; United States / NCI NIH HHS / CA / K22 CA113557-03; United States / NCI NIH HHS / CA / R13 CA132568; United States / NCI NIH HHS / CA / R13 CA132568-02; United States / NCI NIH HHS / CA / CA132568-02; United States / NCI NIH HHS / CA / K22 CA113557; United States / NHLBI NIH HHS / HL / R01 HL082981; United States / NCI NIH HHS / CA / CA113557-03; United States / NHLBI NIH HHS / HL / 5R01HL082981-03; United States / NCI NIH HHS / CA / 3R13CA132568-02
  • [Publication-type] Congresses; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS95430; NLM/ PMC2692866
  •  go-up   go-down


73. Witt O, Deubzer HE, Milde T, Oehme I: HDAC family: What are the cancer relevant targets? Cancer Lett; 2009 May 8;277(1):8-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, several studies have shown that certain HDAC family members are aberrantly expressed in several tumors and have non-redundant function in controlling hallmarks of cancer cells.


74. Yang M, Mo XM, Jin JY, Wu M, Liu B, Liu ZY, Gao XC, Tang WW, Teng GJ: [Diagnostic value of 64 multislice CT in typing of congenital aortic anomaly in neonates and infants]. Zhonghua Yi Xue Za Zhi; 2010 Aug 17;90(31):2167-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 120 pediatric patients (under one year of age) with congenital heart disease (CHD) underwent 64 contrast-enhanced MSCT before a corrective operations.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029654.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


75. Karrman K, Forestier E, Heyman M, Andersen MK, Autio K, Blennow E, Borgström G, Ehrencrona H, Golovleva I, Heim S, Heinonen K, Hovland R, Johannsson JH, Kerndrup G, Nordgren A, Palmqvist L, Johansson B, Nordic Society of Pediatric Hematology, Oncology (NOPHO), Swedish Cytogenetic Leukemia Study Group (SCLSG), NOPHO Leukemia Cytogenetic Study Group (NLCSG): Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome. Genes Chromosomes Cancer; 2009 Sep;48(9):795-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome.
  • Clinical characteristics and cytogenetic aberrations were ascertained and reviewed in a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias (T-ALLs) diagnosed between 1992 and 2006 in the Nordic countries.
  • In conclusion, in this large series of childhood T-ALLs from the Nordic countries, the cytogenetic findings were not associated with risk of therapy failure with the exception of the TCR;other group.
  • [MeSH-major] Chromosome Aberrations. Gene Rearrangement, T-Lymphocyte. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530250.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


76. Holleman A, den Boer ML, Kazemier KM, Beverloo HB, von Bergh AR, Janka-Schaub GE, Pieters R: Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood; 2005 Sep 1;106(5):1817-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia.
  • Drug resistance in childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) is associated with impaired ability to induce apoptosis.
  • To elucidate causes of apoptotic defects, we studied the protein expression of Apaf-1, procaspases-2, -3, -6, -7, -8, -10, and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) in cells from children with acute lymphoblastic leukemia (ALL; n = 43) and acute myeloid leukemia (AML; n = 10).
  • PARP expression was present in all B-lineage samples, but absent in 4 of 15 T-lineage ALL samples and 3 of 10 AML cases, which was not caused by genomic deletions.
  • In conclusion, low baseline expression of PARP and procaspase-2 is related to cellular drug resistance in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Caspases / metabolism. Drug Resistance, Neoplasm / physiology. Poly(ADP-ribose) Polymerases / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism


77. Tude Melo JR, Di Rocco F, Blanot S, Oliveira-Filho J, Roujeau T, Sainte-Rose C, Duracher C, Vecchione A, Meyer P, Zerah M: Mortality in children with severe head trauma: predictive factors and proposal for a new predictive scale. Neurosurgery; 2010 Dec;67(6):1542-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This retrospective study was based on medical records of children with severe traumatic brain injury who were hospitalized at a level I pediatric trauma center between January 2000 and December 2005.
  • Median Glasgow Coma Scale score was 6, and median Pediatric Trauma Score was 4.
  • CONCLUSION: Independent and modifiable mortality predictors could be identified and used for a new grading scale correlated with the risk of mortality in pediatric traumatic brain injury.

  • MedlinePlus Health Information. consumer health - Head Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurgery. 2011 Sep;69(3):E785-6; author reply 786 [21623245.001]
  • (PMID = 21107185.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Loens K, Beck T, Ursi D, Overdijk M, Sillekens P, Goossens H, Ieven M: Evaluation of different nucleic acid amplification techniques for the detection of M. pneumoniae, C. pneumoniae and Legionella spp. in respiratory specimens from patients with community-acquired pneumonia. J Microbiol Methods; 2008 Jun;73(3):257-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. J. Infect. Dis.

  • MedlinePlus Health Information. consumer health - Pneumonia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18378345.001).
  • [ISSN] 0167-7012
  • [Journal-full-title] Journal of microbiological methods
  • [ISO-abbreviation] J. Microbiol. Methods
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


79. Boyle-Vavra S, Ereshefsky B, Wang CC, Daum RS: Successful multiresistant community-associated methicillin-resistant Staphylococcus aureus lineage from Taipei, Taiwan, that carries either the novel Staphylococcal chromosome cassette mec (SCCmec) type VT or SCCmec type IV. J Clin Microbiol; 2005 Sep;43(9):4719-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously reported that 76% of 17 CAMRSA isolates (multilocus sequence type 59) obtained from pediatric patients with skin and soft tissue infections (SSTI) from Taipei did not carry SCCmec types I to IV.
  • A total of 63% (10 of 16) of the SSTI isolates and 61.7% (21 of 34) of the colonization isolates tested were resistant to at least four classes of non-beta-lactam antimicrobials.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2002 Oct 1;35(7):819-24 [12228818.001]
  • [Cites] J Bacteriol. 2002 Jul;184(13):3623-9 [12057957.001]
  • [Cites] Clin Infect Dis. 2003 Jan 15;36(2):131-9 [12522744.001]
  • [Cites] Emerg Infect Dis. 2003 Aug;9(8):978-84 [12967497.001]
  • [Cites] Clin Infect Dis. 2003 Oct 15;37(8):1050-8 [14523769.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4559-64 [14532182.001]
  • [Cites] Clin Infect Dis. 2003 Nov 15;37(10):1384-8 [14583874.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5113-20 [14605147.001]
  • [Cites] JAMA. 2003 Dec 10;290(22):2976-84 [14665659.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jan;48(1):275-80 [14693550.001]
  • [Cites] Antimicrob Agents Chemother. 2004 May;48(5):1823-36 [15105141.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jul;48(7):2637-51 [15215121.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1999 Aug 20;48(32):707-10 [21033181.001]
  • [Cites] Med J Aust. 2004 Aug 16;181(4):228-9 [15310264.001]
  • [Cites] Clin Infect Dis. 2004 Aug 15;39(4):481-7 [15356810.001]
  • [Cites] Clin Infect Dis. 2004 Oct 1;39(7):971-9 [15472848.001]
  • [Cites] J Clin Microbiol. 2004 Oct;42(10):4735-43 [15472334.001]
  • [Cites] J Infect Dis. 2004 Nov 15;190(10):1730-8 [15499526.001]
  • [Cites] Mol Biol Evol. 1987 Jul;4(4):406-25 [3447015.001]
  • [Cites] J Bacteriol. 1991 Dec;173(23):7416-22 [1718947.001]
  • [Cites] Antimicrob Agents Chemother. 1993 Jun;37(6):1219-26 [8328773.001]
  • [Cites] Clin Infect Dis. 1995 Nov;21(5):1308-12 [8589164.001]
  • [Cites] Infect Dis Clin North Am. 1997 Dec;11(4):813-49 [9421702.001]
  • [Cites] JAMA. 1998 Feb 25;279(8):593-8 [9486753.001]
  • [Cites] J Clin Microbiol. 1998 Apr;36(4):1020-7 [9542929.001]
  • [Cites] Pediatr Infect Dis J. 1999 May;18(5):410-4 [10353512.001]
  • [Cites] Clin Infect Dis. 1999 Nov;29(5):1128-32 [10524952.001]
  • [Cites] J Clin Microbiol. 2005 Jan;43(1):132-9 [15634961.001]
  • [Cites] Epidemiol Infect. 2004 Dec;132(6):1091-7 [15635966.001]
  • [Cites] N Engl J Med. 2005 Apr 7;352(14):1445-53 [15814880.001]
  • [Cites] N Engl J Med. 2005 Apr 7;352(14):1485-7 [15814886.001]
  • [Cites] J Infect Dis. 2002 Nov 1;186(9):1344-7 [12402206.001]
  • [Cites] J Clin Microbiol. 2000 Mar;38(3):1008-15 [10698988.001]
  • [Cites] Antimicrob Agents Chemother. 2001 May;45(5):1323-36 [11302791.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jul;45(7):1955-63 [11408208.001]
  • [Cites] Clin Infect Dis. 2001 Oct 1;33(7):990-6 [11528570.001]
  • [Cites] Pediatr Infect Dis J. 2001 Aug;20(8):763-7 [11734738.001]
  • [Cites] Lancet. 2002 Mar 2;359(9308):753-9 [11888586.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Apr;46(4):1147-52 [11897611.001]
  • [ErratumIn] J Clin Microbiol. 2005 Dec;43(12):6223
  • (PMID = 16145133.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ AY894415/ AY894416
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI040481; United States / NIAID NIH HHS / AI / R01 AI40481-01A1; United States / ODCDC CDC HHS / CC / R01 CCR523379
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bacterial Proteins; 0 / Bacterial Toxins; 0 / CcrC protein, Staphylococcus aureus; 0 / Exotoxins; 0 / Leukocidins; 0 / Panton-Valentine leukocidin; 0 / Recombinases
  • [Other-IDs] NLM/ PMC1234068
  •  go-up   go-down


80. Adetifa IM, Ota MO, Jeffries DJ, Hammond A, Lugos MD, Donkor S, Patrick O, Adegbola RA, Hill PC: Commercial interferon gamma release assays compared to the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection in childhood contacts in the Gambia. Pediatr Infect Dis J; 2010 May;29(5):439-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Commercial interferon gamma release assays compared to the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection in childhood contacts in the Gambia.
  • BACKGROUND: We compared the performance of tuberculin skin test (TST), Quantiferon-TB Gold in-tube (QFT-GIT), and T-SPOT.TB in diagnosing latent tuberculosis (LTBI) among childhood TB contacts in a TB endemic setting with high BCG coverage.
  • METHODS: Childhood contacts of newly diagnosed TB patients were tested with TST, QFT-GIT, and T-SPOT.

  • Genetic Alliance. consumer health - Tuberculosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20068506.001).
  • [ISSN] 1532-0987
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U190071468; United Kingdom / Medical Research Council / / MC/ U190081968; United Kingdom / Medical Research Council / /
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Tuberculin; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


81. DiRusso SM, Sullivan T, Risucci D, Nealon P, Slim M: Intubation of pediatric trauma patients in the field: predictor of negative outcome despite risk stratification. J Trauma; 2005 Jul;59(1):84-90; discussion 90-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intubation of pediatric trauma patients in the field: predictor of negative outcome despite risk stratification.
  • Our objective was to analyze outcomes in pediatric intubated trauma patients using a large national pediatric trauma registry.
  • METHODS: The patient population was derived from the last phase of the National Pediatric Trauma Registry, comprising admissions from 1994 through 2002.
  • Compared with nonintubated patients, the odds ratio for field intubation, for non-trauma center, and for trauma center intubation was 14.4, 5.8, and 4.8, respectively (significantly different field vs. either hospital).
  • Although not causal, the magnitude of these differences should lead to future controlled studies of pediatric trauma field intubations.

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Trauma Nurs. 2006 Jul-Sep;13(3):151-3 [17052098.001]
  • (PMID = 16096544.001).
  • [ISSN] 0022-5282
  • [Journal-full-title] The Journal of trauma
  • [ISO-abbreviation] J Trauma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


82. Seifert G, Jesse P, Laengler A, Reindl T, Lüth M, Lobitz S, Henze G, Prokop A, Lode HN: Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett; 2008 Jun 18;264(2):218-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro.
  • In this paper, we describe for the first time the in vivo efficacy and mechanism of action of MT in lymphoblastic leukemia.
  • For this purpose, we first investigated both the cytotoxic effect and the mechanism of action of two standardized aqueous MTs (MT obtained from fir trees (MT-A); MT obtained from pine trees (MT-P)) in a human acute lymphoblastic leukemia (ALL) cell line (NALM-6).
  • Finally, we evaluated the efficacy of MT-A and MT-P in an in vivo SCID-model of pre-B ALL (NALM-6).
  • [MeSH-major] Apoptosis / drug effects. Mistletoe / chemistry. Phytotherapy. Plant Extracts / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18314258.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts; 0 / Plant Lectins
  •  go-up   go-down


83. Yamanouchi H, Kawaguchi N, Mori M, Imataka G, Yamagata T, Hashimoto T, Momoi MY, Eguchi M, Mizuguchi M: Acute infantile encephalopathy predominantly affecting the frontal lobes. Pediatr Neurol; 2006 Feb;34(2):93-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute infantile encephalopathy predominantly affecting the frontal lobes.
  • To establish a novel subtype of acute infantile encephalopathy, the clinical and radiologic features of nine infants with acute encephalopathy involving the bilateral frontal lobes were examined.
  • These unique features suggest that the frontal lobes are the focus of this novel subtype of acute encephalopathy, which we propose to call acute infantile encephalopathy predominantly affecting the frontal lobes.

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458819.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Liu S, Breit S, Danckwardt S, Muckenthaler MU, Kulozik AE: Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. Ann Hematol; 2009 Jul;88(7):613-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activation of Notch1 signaling plays an important role in the pathogenesis of precursor T-cell lymphoblastic leukemia (T-ALL).
  • [MeSH-major] Amyloid Precursor Protein Secretases / physiology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Receptor, Notch1 / antagonists & inhibitors

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057901.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 2-(((3,5-difluorophenyl)acetyl)amino)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)propanamide; 0 / Benzodiazepinones; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


85. Ye J, Qiu WJ, Han LS, Zhang YJ, Zhou JD, Zhang YF, Wu YL, Gu XF: [Diagnosis, treatment and long-term following up of 223 patients with hyperphenylalaninemia detected by neonatal screening programs]. Zhonghua Yu Fang Yi Xue Za Zhi; 2007 May;41(3):189-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis, treatment and long-term following up of 223 patients with hyperphenylalaninemia detected by neonatal screening programs].
  • OBJECTIVE: To investigate the incidence of hyperphenylalaninemia (HPA) caused by different etiologic factors in China and the relationship between the phenylalanine and mental development of patients with HPAs who were diagnosed by neonatal screening and early treated.
  • METHODS: Two hundred and twenty-three patients with HPA detected by neonatal screening programs were refered to us at the age of (41 +/- 27) days after birth.
  • The differential diagnosis was performed by BH(4) (20 mg/kg) loading test, urinary pterin analysis and dihydropteridine reductase (DHPR) activity determination respectively.
  • The control of phenylalanine (Phe) metabolism, growth and mental development were evaluated in all treated patients.
  • Related gene mutation analysis was performed in some patients RESULTS: One hundred and twenty-nine of 223 patients (57.8%) were diagnosed as phenylalanine hydroxylase deficiency (PAHD), 64 patients (28.7%) as BH(4) responsive PAHD, 30 patients (13.5%) as 6-pyruvoyl tetrahydropterin synthase deficiency (PTSD).
  • One hundred and forty-nine patients were followed at age of 4 m - 2 y in our clinic.
  • The 136 of 149 patients were treated according to different etiology at the age of 1.6 m (0.5 - 3.5 m) after birth.
  • Thirteen patients were followed up without the need for treatment.
  • All patients had normal growth development.
  • One hundred and eight (79.4%) of 136 treated patients had normal mental development.
  • The negative correlation (r = -0.439, P < 0.01) between IQ and average Phe levels were observed in 58 patients.
  • Twenty-eight patients were able to go to primary school or even university.
  • Nine kinds of PTS gene mutations were found in 9 cases with PTSD, among which 286G-->A and 259C-->T were most commonly seen, accounting for 45%.
  • Seven kinds of PAH gene mutations were found in 13 cases with BH(4) responsive PAHD with the R241C (43.8%) mutation being the most frequent one.
  • CONCLUSION: The differential diagnosis should be quickly made in all HPA patients detected by neonatal screening.
  • Near 80% patients early treated had normal mental development.
  • The good control of blood Phe level is a key factor for mental development.
  • [MeSH-major] Neonatal Screening / methods. Phenylketonurias / diagnosis. Phenylketonurias / prevention & control
  • [MeSH-minor] China / epidemiology. Female. Follow-Up Studies. Humans. Incidence. Infant. Infant, Newborn. Male. Phenylalanine / blood. Time Factors

  • MedlinePlus Health Information. consumer health - Newborn Screening.
  • MedlinePlus Health Information. consumer health - Phenylketonuria.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708870.001).
  • [ISSN] 0253-9624
  • [Journal-full-title] Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
  • [ISO-abbreviation] Zhonghua Yu Fang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 47E5O17Y3R / Phenylalanine
  •  go-up   go-down


86. Nishima S, Chisaka H, Fujiwara T, Furusho K, Hayashi S, Hiraba K, Kanaya M, Kobayashi N, Kuda N, Kumamoto T, Maeda T, Murayama A, Nagata Y, Narukami H, Nishikawa K, Nishio K, Odajima H, Oka S, Okabe T, Okazaki K, Okazaki T, Okuma M, Ota K, Satomi K, Shimomura M, Suda M, Sunagawa I, Tanaka O, Allergy Prevalence Survey Group, West Japan Pediatric Allergy Association: Surveys on the prevalence of pediatric bronchial asthma in Japan: a comparison between the 1982, 1992, and 2002 surveys conducted in the same region using the same methodology. Allergol Int; 2009 Mar;58(1):37-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveys on the prevalence of pediatric bronchial asthma in Japan: a comparison between the 1982, 1992, and 2002 surveys conducted in the same region using the same methodology.

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma in Children.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050372.001).
  • [ISSN] 1323-8930
  • [Journal-full-title] Allergology international : official journal of the Japanese Society of Allergology
  • [ISO-abbreviation] Allergol Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


87. Khan RA, Narasimhan KL, Tewari MK, Saxena AK: Role of shunts with antisiphon device in treatment of pediatric hydrocephalus. Clin Neurol Neurosurg; 2010 Oct;112(8):687-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of shunts with antisiphon device in treatment of pediatric hydrocephalus.
  • OBJECTIVE: The use of ventriculo-peritoneal shunts having antisiphon device has been reported in adult patients, but there is a dearth of experience with such shunts in pediatric age group.
  • Patients in antisiphon group were treated with shunts with differential valve including antisiphon device (Vygon shunt) while patients in non-antisiphon group were treated with differential valve shunts (Chhabra shunt and Ceredrain).
  • RESULTS: The mean age was 3.5 months and 3.4 months in antisiphon group and non-antisiphon group, respectively.
  • The M:F ratio was 2.3:1 in antisiphon group while it was 3:1 in non-antisiphon group.
  • The mean decrease in OFC was more in non-antisiphon group than antisiphon group during the follow up from 3 months to 6 months while mean decrease in MEI was more in non-antisiphon group from 0 month to 3 months than antisiphon group.
  • There were two cases of shunt overdrainage in non-antisiphon group.
  • The shunt blockage rate was 20% in antisiphon group and 15% in non-antisiphon group, respectively.
  • There was 20% and 15% shunt infection rate in antisiphon group and non-antisiphon group, respectively.

  • Genetic Alliance. consumer health - Hydrocephalus.
  • MedlinePlus Health Information. consumer health - Hydrocephalus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20646829.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  •  go-up   go-down


88. Krahn AD, Simpson CS, Parkash R, Yee R, Champagne J, Healey JS, Cameron D, Thibault B, Mangat I, Tung S, Sterns L, Birnie DH, Exner DV, Sivakumaran S, Davies T, Coutu B, Crystal E, Wolfe K, Verma A, Stephenson EA, Sanatani S, Gow R, Connors S, Paredes FA, Turabian M, Kus T, Gardner M, Essebag V: Utilization of a national network for rapid response to the Medtronic Fidelis lead advisory: the Canadian Heart Rhythm Society Device Advisory Committee. Heart Rhythm; 2009 Apr;6(4):474-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Committee membership is broadly representative of the Canadian device community, including both academic and nonacademic centers, adult and pediatric specialists, and includes balanced regional representation.

  • MedlinePlus Health Information. consumer health - Pacemakers and Implantable Defibrillators.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Heart Rhythm. 2009 Apr;6(4):478-9 [19324306.001]
  • (PMID = 19324305.001).
  • [ISSN] 1556-3871
  • [Journal-full-title] Heart rhythm
  • [ISO-abbreviation] Heart Rhythm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, Neuberg D, Protopopov A, Winter SS, Larson RS, Borowitz MJ, Silverman LB, Chin L, Hunger SP, Jamieson C, Sallan SE, Look AT: Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood; 2010 Apr 08;115(14):2845-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.
  • To further unravel the molecular pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL), we performed high-resolution array comparative genomic hybridization on diagnostic specimens from 47 children with T-ALL and identified monoallelic or biallelic LEF1 microdeletions in 11% (5 of 47) of these primary samples.
  • [MeSH-major] Codon, Terminator. Lymphoid Enhancer-Binding Factor 1 / genetics. Neoplasm Proteins / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Sequence Deletion

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):781-5 [10693808.001]
  • [Cites] Blood. 2009 Jul 16;114(3):647-50 [19458356.001]
  • [Cites] Nucleic Acids Res. 2001 Apr 1;29(7):1410-9 [11266540.001]
  • [Cites] Nat Genet. 2001 May;28(1):53-7 [11326276.001]
  • [Cites] Stem Cells. 2001;19(3):165-79 [11359942.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7537-44 [11604490.001]
  • [Cites] Development. 2002 Jan;129(1):95-109 [11782404.001]
  • [Cites] Dev Biol. 2002 Apr 1;244(1):1-8 [11900454.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):267-73 [12808457.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jun;50(3):223-61 [15182827.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):552-9 [15295048.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Genes Dev. 1994 Nov 15;8(22):2691-703 [7958926.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Immunity. 1998 Jan;8(1):11-20 [9462507.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] J Exp Med. 2005 Jun 6;201(11):1715-23 [15928199.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1283-98 [16564017.001]
  • [Cites] Nat Med. 2006 Apr;12(4):395-7 [16565724.001]
  • [Cites] Nat Genet. 2006 May;38(5):500-1 [16642009.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1184-7 [16572206.001]
  • [Cites] J Cell Sci. 2007 May 1;120(Pt 9):1646-53 [17452626.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5463-72 [17317856.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1429-38 [17495134.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2344-53 [17690692.001]
  • [Cites] J Exp Med. 2007 Dec 24;204(13):3059-66 [18070937.001]
  • [Cites] J Exp Med. 2008 Mar 17;205(3):515-22 [18316418.001]
  • [Cites] Cell. 2008 May 30;133(5):864-77 [18510930.001]
  • [Cites] Sci Signal. 2008;1(45):ra12 [19001663.001]
  • [Cites] Mol Cell Biol. 2008 Dec;28(24):7368-79 [18852287.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):147-56 [19147408.001]
  • [Cites] Nucleic Acids Res. 2000 May 1;28(9):1994-2003 [10756202.001]
  • (PMID = 20124220.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1K08CA133103; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / K08 CA133103-04; United States / NCI NIH HHS / CA / K08 CA133103-01; United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / K08 CA133103; United States / NCI NIH HHS / CA / K08 CA133103-03; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA98413; United States / NCI NIH HHS / CA / K08 CA133103-02; United States / NCI NIH HHS / CA / P01 CA068484; United States / NCI NIH HHS / CA / 5P01CA68484
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Codon, Terminator; 0 / LEF1 protein, human; 0 / Lymphoid Enhancer-Binding Factor 1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2854430
  •  go-up   go-down


90. Scaruffi P, Stigliani S, Coco S, Valdora F, De Vecchi C, Bonassi S, Tonini GP: Transcribed-ultra conserved region expression profiling from low-input total RNA. BMC Genomics; 2010;11:149
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recent findings that they are significantly altered in adult chronic lymphocytic leukemias, carcinomas, and pediatric neuroblastomas lead to the hypothesis that UCRs may play a role in tumorigenesis.
  • Direct comparison of non-amplified with amplified cDNA in two neuroblastoma cell lines showed that the amplification approach increases sensitivity and repeatability in T-UCR quantification.
  • CONCLUSIONS: We demonstrated that the quantification procedure shown here is an accurate and reliable technique for genome-wide non coding gene (i.e., UCRs) profiling using small amounts of RNA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 2003 Dec;283(1-2):291-306 [14659920.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2527-8; author reply 2528-31 [14671651.001]
  • [Cites] Science. 2004 May 28;304(5675):1321-5 [15131266.001]
  • [Cites] Bioinformatics. 2004 Aug 4;20 Suppl 1:i40-8 [15262779.001]
  • [Cites] Biotechniques. 2004 Nov;37(5):854-7 [15560142.001]
  • [Cites] BMC Cancer. 2009;9:441 [20003513.001]
  • [Cites] Nature. 2006 May 4;441(7089):87-90 [16625209.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):215-29 [17785203.001]
  • [Cites] Nucleic Acids Res. 2008 Dec;36(21):e143 [18940866.001]
  • [Cites] Clin Chem. 2009 Apr;55(4):611-22 [19246619.001]
  • [Cites] Nucleic Acids Res. 2009 Apr;37(7):2065-9 [19223324.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1973-81 [16123149.001]
  • (PMID = 20199688.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Untranslated
  • [Other-IDs] NLM/ PMC2838852
  •  go-up   go-down


91. Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M, Saito N, Yang SM, Iwamoto C, Okamura J, Liu KY, Huang XJ, Lu DP, Shultz LD, Harada M, Ishikawa F: CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia; 2008 Jun;22(6):1207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
  • In human acute myelogenous leukemia (AML), the leukemia stem cells (LSCs) have been phenotypically restricted within the CD34+CD38- fraction.
  • To understand the origin of malignant cells in primary human B-precursor acute lymphocytic leukemia (B-ALL), we established a novel in vivo xenotransplantation model.
  • Purified CD34+CD38+CD19+, CD34+CD38-CD19+ and CD34+CD38-CD19- bone marrow (BM) or peripheral blood (PB) cells from three pediatric B-ALL patients were intravenously injected into sublethally irradiated newborn NOD/SCID/IL2rgamma(null) mice.
  • The identification of CD34+CD38+CD19+ self-renewing B-ALL cells proposes a hierarchy of leukemia-initiating cells (LICs) distinct from that of AML.
  • [MeSH-major] Antigens, CD19 / metabolism. Antigens, CD34 / metabolism. Antigens, CD38 / metabolism. Hematopoietic Stem Cells / pathology. Neoplastic Stem Cells / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl>/SzJ (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418410.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


92. Dellefave LM, Pytel P, Mewborn S, Mora B, Guris DL, Fedson S, Waggoner D, Moskowitz I, McNally EM: Sarcomere mutations in cardiomyopathy with left ventricular hypertrabeculation. Circ Cardiovasc Genet; 2009 Oct;2(5):442-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A second pediatric patient presented with heart failure and was found to carry a de novo MYH7 R369Q mutation.
  • This patient had a family history of congestive heart failure, including pediatric onset cardiomyopathy where 3 individuals in the family were found to have the MYH7 mutation R1250W.

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20031619.001).
  • [ISSN] 1942-3268
  • [Journal-full-title] Circulation. Cardiovascular genetics
  • [ISO-abbreviation] Circ Cardiovasc Genet
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00138931
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / MYH7 protein, human; 0 / myosin-binding protein C; EC 3.6.1.- / Cardiac Myosins; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


93. Yanovitch T, Wallace DK, Freedman SF, Enyedi LB, Kishnani P, Worley G, Crissman B, Burner E, Young TL: The accuracy of photoscreening at detecting treatable ocular conditions in children with Down syndrome. J AAPOS; 2010 Dec;14(6):472-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy of photoscreening at detecting treatable ocular conditions in children with Down syndrome.
  • BACKGROUND: Children with Down syndrome (DS) have an increased prevalence of ocular disorders, including amblyopia, strabismus, and refractive error.
  • Health maintenance guidelines from the Down Syndrome Medical Interest Group recommend ophthalmologic examinations every 1 to 2 years for these children.
  • Photoscreening may be a cost-effective option for subsequent screening evaluations after an initial complete examination, but no study has evaluated the accuracy of photoscreening in children with DS.
  • The purpose of this study is to determine the sensitivity, specificity, and positive and negative predictive values of photoscreening in detecting treatable ocular conditions in children with DS.
  • METHODS: Photoscreening and complete ophthalmologic evaluations were performed in 50 consecutive 3- to 10-year-old children with DS.
  • Sensitivity, specificity, and positive and negative predictive values were calculated with the use of ophthalmologic examination findings as the reference standard.
  • RESULTS: Most children were able to complete photoscreening (94% with Medical Technology and Innovations [MTI] and 90% with Visiscreen OSS-C [VR]).
  • Many children had an identified diagnosis on ophthalmologic examination (n = 46, 92%).
  • Of these, approximately one-half (n = 27, 54%) had one or more condition(s) requiring treatment.
  • Both the MTI and VR photoscreening devices had a sensitivity of 93% (95% confidence interval 0.76-0.99) for detecting treatable ocular conditions.
  • The specificities for the MTI and VR photoscreening were 0.35 (0.18-0.57) and 0.55 (0.34-0.74), respectively.
  • CONCLUSIONS: Photoscreening is sensitive but less specific at detecting treatable ocular conditions in children with DS.
  • In specific instances, the use of photoscreening in the DS population has the potential to save time and expense related to routine eye examinations, particularly in children with a normal baseline comprehensive examination.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.
  • [Cites] J Pediatr Ophthalmol Strabismus. 2009 Mar-Apr;46(2):83-6 [19343969.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 2009 Mar-Apr;46(2):76-82 [19343968.001]
  • [Cites] J AAPOS. 2009 Feb;13(1):51-7 [19121596.001]
  • [Cites] Semin Ophthalmol. 2008 Sep-Oct;23(5):294-7 [19085430.001]
  • [Cites] Binocul Vis Strabismus Q. 2008;23(2):83-94 [18702611.001]
  • [Cites] Ophthalmology. 2008 Jul;115(7):1229-1236.e1 [17953989.001]
  • [Cites] Eye (Lond). 1999 Jun;13 ( Pt 3a):363-8 [10624435.001]
  • [Cites] Alaska Med. 2000 Jul-Sep;42(3):58-72 [11042938.001]
  • [Cites] Eye (Lond). 2002 Nov;16(6):710-4 [12439664.001]
  • [Cites] Br J Ophthalmol. 2003 Jul;87(7):909-16 [12812897.001]
  • [Cites] J AAPOS. 2003 Oct;7(5):314-6 [14566312.001]
  • [Cites] Am Fam Physician. 2003 Oct 15;68(8):1664, 1666 [14596454.001]
  • [Cites] Binocul Vis Strabismus Q. 2003;18(4):233-40 [14653776.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 2004 May-Jun;41(3):150-8 [15206600.001]
  • [Cites] Clin Pediatr (Phila). 1989 Aug;28(8):355-8 [2527102.001]
  • [Cites] Acta Ophthalmol Scand Suppl. 1995;(214):26-38; discussion 39-40 [8574881.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 1996 Mar-Apr;33(2):104-13 [8965234.001]
  • [Cites] Am J Ophthalmol. 1996 Aug;122(2):236-44 [8694092.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 1997 Jul-Aug;34(4):217-22; quiz 247-8 [9253735.001]
  • [Cites] Pediatr Neurol. 1997 May;16(4):311-4 [9258964.001]
  • [Cites] J AAPOS. 2005 Apr;9(2):114-20 [15838437.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 2005 Nov-Dec;42(6):360-4 [16382561.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 2006 Jan-Feb;43(1):27-30 [16491722.001]
  • [Cites] J AAPOS. 2006 Feb;10(1):44-8 [16527679.001]
  • [Cites] Clin Exp Optom. 2006 May;89(3):150-4 [16637969.001]
  • [Cites] Ophthalmology. 2006 Jul;113(7):1146-53 [16675019.001]
  • [Cites] Ophthalmology. 2009 Nov;116(11):2128-34.e1-2 [19762084.001]
  • [Cites] Acta Ophthalmol Scand. 2006 Dec;84(6):807-11 [17083543.001]
  • [Cites] Arch Ophthalmol. 2008 Apr;126(4):489-92 [18413517.001]
  • [Cites] Afr J Med Med Sci. 2006 Sep;35(3):365-8 [17312746.001]
  • (PMID = 21168069.001).
  • [ISSN] 1528-3933
  • [Journal-full-title] Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
  • [ISO-abbreviation] J AAPOS
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / EY016333-05; United States / NEI NIH HHS / EY / K12 EY016333; United States / NEI NIH HHS / EY / K12 EY016333-05
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS256994; NLM/ PMC3042280
  •  go-up   go-down


94. Reinehr T, Widhalm K, l'Allemand D, Wiegand S, Wabitsch M, Holl RW, APV-Wiss STudy Group and German Competence Net Obesity: Two-year follow-up in 21,784 overweight children and adolescents with lifestyle intervention. Obesity (Silver Spring); 2009 Jun;17(6):1196-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred twenty-nine centers specialized in outpatient pediatric obesity care participated in this quality assessment.

  • MedlinePlus Health Information. consumer health - Weight Control.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584877.001).
  • [ISSN] 1930-7381
  • [Journal-full-title] Obesity (Silver Spring, Md.)
  • [ISO-abbreviation] Obesity (Silver Spring)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Aucella F, Bisceglia L, De Bonis P, Gigante M, Caridi G, Barbano G, Mattioli G, Perfumo F, Gesualdo L, Ghiggeri GM: WT1 mutations in nephrotic syndrome revisited. High prevalence in young girls, associations and renal phenotypes. Pediatr Nephrol; 2006 Oct;21(10):1393-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 mutations in nephrotic syndrome revisited. High prevalence in young girls, associations and renal phenotypes.
  • WT1 mutations have been considered a rare cause of nephrotic syndrome but recent reports challenge this assumption.
  • Exclusion of inherited forms is a basic point in any therapeutic strategy to nephrotic syndrome since they do not respond to drugs.
  • We screened for WT1 mutations in 200 patients with nephrotic syndrome: 114 with steroid resistance (SRNS) and 86 with steroid dependence (SDNS) for whom other inherited forms of nephrotic syndrome (NPHS2, CD2AP) had been previously excluded.
  • Three girls out of 32 of the group with steroid resistance under 18 years presented classical WT1 splice mutations (IVS9+5G>A, IVS9+4C>T) of Frasier syndrome.
  • Another one presented a mutation coding for an amino acid change (D396N) at exon 9 that is typical of Denys-Drash syndrome.
  • All presented resistance to drugs and developed end stage renal failure within 15 years.
  • Two girls of the Frasier group presented a 46 XY karyotype with streak gonads while one was XX and had normal gonad morphology.
  • In the two cases with IVS9+5G>A renal pathology was characterized by capillary wall thickening with deposition of IgG and C3 in one that was interpreted as a membrane pathology.
  • Foam cells were diffuse in tubule-interstitial areas.
  • In conclusion, WT1 splice mutations are not rare in females under 18 years with SRNS.
  • This occurs in absence of a clear renal pathology picture and frequently in absence of phenotype change typical of Frasier syndrome.
  • In adults and children with SDNS, screening analysis is of no clinical value.
  • WT1 hot spot mutation analysis should be routinely done in children with SRNS; if the molecular screening anticipates any further therapeutic approach it may modify the long term therapeutic strategy.
  • [MeSH-major] Kidney / pathology. Mutation / genetics. Nephrotic Syndrome / genetics. Nephrotic Syndrome / pathology. Phenotype. WT1 Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. DNA Mutational Analysis. Denys-Drash Syndrome / genetics. Denys-Drash Syndrome / pathology. Drug Resistance. Exons / genetics. Female. Frasier Syndrome / genetics. Frasier Syndrome / pathology. Genetic Testing. Humans. Karyotyping. Male. Prevalence. Sex Factors. Steroids / pharmacology

  • Genetic Alliance. consumer health - Young syndrome.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 1998 Apr;62(4):824-33 [9529364.001]
  • [Cites] Clin Ther. 2004 Sep;26(9):1411-8 [15531003.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3554-8 [8170946.001]
  • [Cites] J Am Soc Nephrol. 1999 Oct;10(10):2219-23 [10505700.001]
  • [Cites] Am J Kidney Dis. 2003 May;41(5):1110-5 [12722046.001]
  • [Cites] Nephrol Dial Transplant. 2003 Apr;18(4):823-5 [12637656.001]
  • [Cites] Hum Mol Genet. 1992 Aug;1(5):301-5 [1338906.001]
  • [Cites] Pediatr Res. 2005 May;57(5 Pt 2):54R-61R [15817495.001]
  • [Cites] Science. 1993 Dec 24;262(5142):2057-9 [8266105.001]
  • [Cites] Kidney Int. 2004 Aug;66(2):564-70 [15253707.001]
  • [Cites] J Am Soc Nephrol. 1999 Oct;10(10):2215-8 [10505699.001]
  • [Cites] Cell. 1990 Feb 9;60(3):509-20 [2154335.001]
  • [Cites] Clin Nephrol. 1999 Jan;51(1):62-3 [9988151.001]
  • [Cites] Lancet. 1974 Aug 24;2(7878):423-7 [4137139.001]
  • [Cites] Kidney Int. 1981 Dec;20(6):765-71 [7334749.001]
  • [Cites] Cell. 2001 Aug 10;106(3):319-29 [11509181.001]
  • [Cites] Genomics. 1992 Apr;12(4):807-13 [1572653.001]
  • [Cites] Hum Mol Genet. 1998 Apr;7(4):709-14 [9499425.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):467-70 [9398852.001]
  • [Cites] Hum Mutat. 1999;14(6):466-70 [10571943.001]
  • [Cites] J Am Soc Nephrol. 2003 May;14(5):1278-86 [12707396.001]
  • [Cites] Pediatr Res. 2006 Feb;59(2):325-31 [16439601.001]
  • (PMID = 16909243.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Steroids; 0 / WT1 Proteins
  •  go-up   go-down


96. Huang S, Rutar T, Bloomer M, Crawford JB: Analysis of clinical misdiagnoses in children treated with enucleation. Arch Ophthalmol; 2010 Aug;128(8):1009-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate discordant clinical and pathological diagnoses leading to pediatric enucleations over time.
  • METHODS: All pathology reports of pediatric enucleation specimens (subjects aged 0 to 18 years) from 1960 to 2008 were reviewed.
  • RESULTS: Of 729 pediatric patients (746 eyes) who had enucleation from 1960 to 2008, 29 patients (4.0%) and 30 eyes (4.0%) had discordant clinical and pathological diagnoses.
  • CONCLUSIONS: Misdiagnoses leading to pediatric enucleation have decreased during the past 5 decades, likely owing to improved diagnostic techniques.

  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Ophthalmol. 2011 May;129(5):673-4; author reply 674-5 [21555629.001]
  • (PMID = 20697001.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / P30 EY002162-31
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Vesikari T, Van Damme P, Lindblad N, Pfletschinger U, Radley D, Ryan D, Vuocolo S, Haupt RM, Guris D: An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J; 2010 Apr;29(4):314-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
  • BACKGROUND: GARDASIL/SILGARD is a quadrivalent human papillomavirus (HPV) vaccine with activity against HPV 6/11/16/18.
  • In many countries, GARDASIL is recommended for routine use among adolescents at the same age as other vaccines.
  • In this study, we evaluated the immunogenicity and safety of GARDASIL administered concomitantly with REPEVAX (diphtheria, tetanus, acellular pertussis, and poliomyelitis vaccine).
  • METHODS: This was an open-label, randomized, multicenter study.
  • We enrolled males (n = 260) and females (n = 583) aged 11 to 17 years.
  • All subjects received a 0.5 mL dose of GARDASIL at day 1, month 2, and month 6, and a 0.5 mL dose of REPEVAX either on day 1 (opposite limb from GARDASIL) or at month 1.
  • Antibody levels for all vaccine components were measured.
  • We monitored systemic and injection-site adverse experiences (AEs) and serious adverse experiences.
  • RESULTS: Immune response for all GARDASIL antigens following concomitant administration of the vaccines was demonstrated noninferior to nonconcomitant administration.
  • Seroconversion for HPV 6, 11, 16, and 18 was >99.7% in both concomitant and nonconcomitant vaccination groups.
  • For REPEVAX, noninferiority of immune response was established for diphtheria, tetanus, and all polio and pertussis antigens.
  • Concomitant administration of the 2 vaccines was generally well-tolerated, although there was a small increase in headache and injection-site swelling in the concomitant group.
  • CONCLUSION: Overall, concomitant administration of GARDASIL and REPEVAX was generally well-tolerated and did not interfere with the immune response to either vaccine.
  • Concomitant administration of vaccines would minimize the number of visits required to deliver each vaccine individually.
  • [MeSH-major] Antibodies, Bacterial / blood. Antibodies, Viral / blood. Diphtheria-Tetanus-acellular Pertussis Vaccines. Papillomavirus Vaccines. Poliovirus Vaccines
  • [MeSH-minor] Adolescent. Alphapapillomavirus / immunology. Bordetella pertussis / immunology. Child. Diphtheria / immunology. Diphtheria / prevention & control. Diphtheria Toxoid / administration & dosage. Diphtheria Toxoid / immunology. Female. Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18. Humans. Male. Papillomavirus Infections / immunology. Papillomavirus Infections / prevention & control. Poliomyelitis / immunology. Poliomyelitis / prevention & control. Tetanus / immunology. Tetanus / prevention & control. Tetanus Toxoid / administration & dosage. Tetanus Toxoid / immunology. Treatment Outcome. Whooping Cough / immunology. Whooping Cough / prevention & control

  • Genetic Alliance. consumer health - Diphtheria.
  • Genetic Alliance. consumer health - Poliomyelitis.
  • Genetic Alliance. consumer health - Tetanus.
  • MedlinePlus Health Information. consumer health - Tetanus, Diphtheria, and Pertussis Vaccines.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952980.001).
  • [ISSN] 1532-0987
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antibodies, Viral; 0 / Diphtheria Toxoid; 0 / Diphtheria-Tetanus-acellular Pertussis Vaccines; 0 / Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; 0 / Papillomavirus Vaccines; 0 / Poliovirus Vaccines; 0 / Tetanus Toxoid
  •  go-up   go-down


98. King KM, Damaraju VL, Vickers MF, Yao SY, Lang T, Tackaberry TE, Mowles DA, Ng AM, Young JD, Cass CE: A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol; 2006 Jan;69(1):346-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2-Chloro-9-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)adenine (Cl-F-ara-A, clofarabine), a purine nucleoside analog with structural similarity to 2-chloro-2'-deoxyadenosine (Cl-dAdo, cladribine) and 9-beta-d-arabinofuranosyl-2-fluoroadenine (F-ara-A, fludarabine), has activity in adult and pediatric leukemias.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234483.001).
  • [ISSN] 0026-895X
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Membrane Transport Proteins; 0 / Recombinant Proteins; 0 / cif nucleoside transporter; 47M74X9YT5 / Cladribine; 762RDY0Y2H / clofarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


99. Luria D, Rosenthal E, Steinberg D, Kodman Y, Safanaiev M, Amariglio N, Avigad S, Stark B, Izraeli S, Israel National Study Group of Childhood ALL: Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia. Cytometry B Clin Cytom; 2010 Nov;78(6):365-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Minimal residual disease (MRD) is a powerful prognostic indicator in childhood acute lymphoblastic leukemia (ALL).
  • METHODS: We compared FC-MRD of identical bone marrow samples processed as either Ficoll separated mononuclear cells or lyse and wash nucleated cells (NC) in two central laboratories of a national multicenter childhood ALL study.
  • CONCLUSIONS: FC-MRD analysis of childhood ALL is a robust method during the earliest phases of induction therapy in a multicentric setting.
  • [MeSH-major] Flow Cytometry / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 International Clinical Cytometry Society.
  • (PMID = 20632326.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Dina A; Gali A; Ami B; Bella B; Yoav B; Ronit E; Herzel G; Yosef K; Hagit M; Dalia S; Michael W
  •  go-up   go-down


100. Abadir S, Edouard T, Julia S: Severe aortic valvar stenosis in familial Noonan syndrome with mutation of the PTPN11 gene. Cardiol Young; 2007 Feb;17(1):95-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Echocardiography. Fatal Outcome. Humans. Infant, Newborn. Male. Mutation. Protein Tyrosine Phosphatase, Non-Receptor Type 11

  • Genetic Alliance. consumer health - Noonan Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184563.001).
  • [ISSN] 1047-9511
  • [Journal-full-title] Cardiology in the young
  • [ISO-abbreviation] Cardiol Young
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down






Advertisement